{"id":143,"date":"2019-01-29T15:35:11","date_gmt":"2019-01-29T06:35:11","guid":{"rendered":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol-test\/?page_id=143"},"modified":"2025-11-10T15:20:20","modified_gmt":"2025-11-10T06:20:20","slug":"kokunai","status":"publish","type":"page","link":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/publications\/kokunai\/","title":{"rendered":"\u56fd\u5185\u5b66\u4f1a\u767a\u8868"},"content":{"rendered":"

2025<\/strong><\/p>\n

    \n
  1. Munekata T, Matsuda A, Maishi N, Miyamoto I, Hida Y, Hida<\/u> K<\/u>. Analysis of tumor metastasis suppression mechanism by the effects of beta-blockers on vascular endothelial cells, \u30dd\u30b9\u30bf\u30fc, \u7b2c33\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.11.1-2\uff08\u6771\u4eac\uff09<\/li>\n
  2. \u6d2a \u8aed\u7469 \uff0c\u4f59 \u00a0\u9e97\uff0c\u9ad8\u6a4b\u90c1\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530 \u00a0\u5f69 \uff0c\u6a0b\u7530\u6cf0\u6d69, \u5bae\u672c\u90c1\u4e5f, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aFunctional Analysis of miR-199a-3p in Tumor Endothelial Cells, \u53e3\u6f14, \u7b2c58\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff08\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u75c5\u7406\u5206\u79d1\u4f1a\uff09, 2025.10.18\uff08\u672d\u5e4c\uff09<\/li>\n
  3. \u677e\u7530 \u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u68ee\u672c\u6d69\u53f2, \u00a0\u83ca\u5730 \u00a0\u592e\uff0cYu L\uff0c\u8d64\u5800\u6c38\u502b\u9999\uff0c \u624b\u4ee3\u6728\u5b5d\u4ec1\uff0c\u7531\u826f\u5468\u5b50\uff0c\u7a4d\u7530\u5353\u4e5f\uff0c\u4f50\u85e4\u5cf0\u5609\uff0c\u8c37\u5d8b\u6210\u6a39\uff0c\u7551\u4e2d\u4f73\u5948\u5b50\uff0c\u7551\u4e2d \u00a0\u8c4a\u00a0 \uff0c\u677e\u672c\u9686\u5150\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u897f\u539f\u5e83\u53f2\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: \u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u30b2\u30ce\u30e0\u7570\u5e38, \u53e3\u6f14, \u7b2c58\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff08\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u75c5\u7406\u5206\u79d1\u4f1a\uff09, 2025.10.18\uff08\u672d\u5e4c\uff09<\/li>\n
  4. \u624b\u4ee3\u6728\u5b5d\u4ec1, \u6b66\u7530 \u907c, \u8429\u91ce\u88d5\u592a\uff0c\u9593\u77f3\u5948\u6e56 \uff0c\u7a4d\u7530\u5353\u4e5f\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u4f0a\u85e4 \u00a0\u822a\uff0c\u685c\u4e95\u512a\u5f25\uff0c Mahmoud Younis\uff0c \u4f50\u3005\u6728\u9053\u4ec1 \uff0c \u5927\u5834\u9756\u5b50\uff0c \u677e\u7530 \u00a0\u5f69 \uff0c \u539f\u5cf6\u79c0\u5409\uff0c\u6fa4 \u00a0\u6d0b\u6587,\u00a0 \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCOVID-19\u91cd\u75c7\u5316\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308bCelastrol\u306e\u52b9\u679c\u691c\u8a0e, \u53e3\u6f14, \u7b2c58\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff08\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u75c5\u7406\u5206\u79d1\u4f1a\uff09, 2025.10.18\uff08\u672d\u5e4c\uff09<\/li>\n
  5. Dawood RIH\uff0cRen Z\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u65b0\u5c71\u3000\u5b97\uff0cYu L, Sun W\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCharacterization of High Endothelial Venules \uff08HEVs\uff09 in Oral Squamous Cell Carcinoma \uff08OSCC\uff09, \u53e3\u6f14, \u7b2c131\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a, 2025.10.11\uff08\u672d\u5e4c\uff09<\/li>\n
  6. \u5343\u7530\u5065\u535a\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u4f50\u85e4\u5cf0\u5609\uff0cJia Z\uff0c\u4e2d\u5cf6\u5b5d\u5e73\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5c0f\u5ddd\u7f8e\u9999\u5b50\uff0c\u5927\u5ee3\u6d0b\u4e00\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>, \u8fd1\u8d64\u5916\u7dda\u5149\u514d\u75ab\u7642\u6cd5\u306b\u3088\u308b\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306e\u75c5\u7406\u7d44\u7e54\u5b66\u7684\u89e3\u6790, \u53e3\u6f14, \u7b2c131\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a, 2025.10.11\uff08\u672d\u5e4c\uff09<\/li>\n
  7. \u685c\u4e95\u512a\u5f25\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u57ce\u6238\u5e79\u592a, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u52a0\u9f62\u306b\u4f34\u3046\u8840\u7ba1\u5185\u76ae\u7d30\u80deSARS-CoV-2\u611f\u67d3\u5897\u5f37\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, \u7b2c25\u56de\u65e5\u672c\u6b6f\u79d1\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2025.9.28-28\uff08\u6a2a\u6d5c, \u30aa\u30f3\u30c7\u30de\u30f3\u30c9\uff09<\/li>\n
  8. \u8d64\u5800\u6c38\u502b\u9999, \u677e\u7530 \u5f69, \u5bae\u672c\u90c1\u4e5f, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aPorphyromonas gingivalis\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u9593\u63a5\u7740\u306e\u4f4e\u4e0b\u3092\u4ecb\u3057\u305f\u816b\u760d\u8ee2\u79fb\u8a98\u5c0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c25\u56de\u65e5\u672c\u6b6f\u79d1\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2025.9.28-28\uff08\u6a2a\u6d5c, \u30aa\u30f3\u30c7\u30de\u30f3\u30c9\uff09, \u30dd\u30b9\u30bf\u30fc\u8cde\u53d7\u8cde<\/li>\n
  9. \u5b97\u7247\u52c7\u53f2, \u677e\u7530\u3000\u5f69, \u5bae\u672c\u90c1\u4e5f, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u03b2\u906e\u65ad\u85ac\u306e\u8840\u7ba1\u5185\u76ae\u3092\u4ecb\u3057\u305f\u304c\u3093\u8ee2\u79fb\u306b\u5bfe\u3059\u308b\u4f5c\u7528\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, \u7b2c25\u56de\u65e5\u672c\u6b6f\u79d1\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2025.9.28-28\uff08\u6a2a\u6d5c, \u30aa\u30f3\u30c7\u30de\u30f3\u30c9\uff09, \u30dd\u30b9\u30bf\u30fc\u8cde\u30fb\u5927\u5b66\u9662\u751f\u90e8\u9580\u53d7\u8cde<\/li>\n
  10. \u5b97\u7247\u52c7\u53f2, \u677e\u7530\u3000\u5f69, \u9593\u77f3\u5948\u6e56, \u5bae\u672c\u90c1\u4e5f, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u03b2\u906e\u65ad\u85ac\u306e\u8840\u7ba1\u5185\u76ae\u3078\u306e\u4f5c\u7528\u3092\u4ecb\u3057\u305f\u304c\u3093\u8ee2\u79fb\u306b\u4e0e\u3048\u308b\u5f71\u97ff\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e, \u7b2c84\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a. 2025.9.27\uff08\u91d1\u6ca2\uff09<\/li>\n
  11. \u4f0a\u85e4\u7965\u592a\u90ce, \u698a\u539f\u3000\u7d14, \u4f50\u85e4\u5cf0\u5609, \u5e84\u53f8\u54f2\u660e, \u53e4\u7530\u3000\u6075, \u9ad8\u6a4b\u5b8f\u5178, \u8fbb\u3000\u5eb7\u4ecb, \u68ee\u6c38\u5927\u4eae, \u5609\u5cf6\u76f8\u88d5, \u5317\u4e95\u79c0\u5178, \u7551\u4e2d\u4f73\u5948\u5b50, \u7551\u4e2d\u3000\u8c4a, \u6a0b\u7530\u4eac\u5b50<\/u>, \u91ce\u53e3\u5353\u90ce, \u4eca\u91ce\u3000\u54f2\uff1a\u201c\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u304a\u3044\u3066\u30df\u30c3\u30c9\u30ab\u30a4\u30f3\u306fAKT\u7d4c\u8def\u3092\u4ecb\u3057\u3066\u816b\u760d\u5897\u6b96\u3068Cispilation\u8010\u6027\u3092\u5236\u5fa1\u3059\u308b\u201d, \u7b2c84\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a. 2025.9.27\uff08\u91d1\u6ca2\uff09<\/li>\n
  12. \u5b97\u7247\u52c7\u53f2\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5bae\u672c\u90c1\u4e5f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8840\u7ba1\u5185\u76ae\u3078\u306e\u4f5c\u7528\u3092\u4ecb\u3057\u305f\u03b2\u906e\u65ad\u85ac\u306e\u304c\u3093\u8ee2\u79fb\u306b\u53ca\u307c\u3059\u5f71\u97ff\u306e\u691c\u8a0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c36\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2025.9.2-4\uff08\u5ca1\u5c71\uff09<\/li>\n
  13. \u5b97\u7247\u52c7\u53f2\uff1a\u03b2 \u906e\u65ad\u85ac\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3078\u306e\u4f5c\u7528\u3092\u4ecb\u3057\u305f\u304c\u3093\u8ee2\u79fb\u6291\u5236\u6a5f\u69cb, \u53e3\u6f14, \u7b2c20\u56de\u5148\u7aef\u6b6f\u5b66\u30b9\u30af\u30fc\u30eb2025, 2025.8.29\uff08\u798f\u5ca1\uff09<\/li>\n
  14. \u6a0b\u7530\u4eac\u5b50<\/span>\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff1a\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\u3068\u816b\u760d\u514d\u75ab, Tumor Vascular Diversity and Tumor Immunity, \u53e3\u6f14, \u30dd\u30b9\u30bf\u30fc, \u7b2c29\u56de\u65e5\u672c\u304c\u3093\u514d\u75ab\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2025.7.26\uff08\u540d\u53e4\u5c4b\uff09<\/span><\/li>\n
  15. Akahori E, Yu L, Maishi N, Matsuda A, Hasebe A, Hida Y, Miyamoto I, <\/span>Hida K<\/span>:Porphyromonas gingivalis, a periodontal disease-causing bacterium, promotes tumor metastasis by disrupting the vascular endothelial barrier, poster, The 43rd Sapporo International Cancer Symposium, 2025.7.5-6, Sapporo<\/span><\/li>\n
  16. \u5b97\u7247\u52c7\u53f2, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u8840\u7ba1\u5185\u76ae\u3078\u306e\u4f5c\u7528\u3092\u4ecb\u3057\u305f\u03b2\u906e\u65ad\u85ac\u306e\u304c\u3093\u8ee2\u79fb\u306b\u4e0e\u3048\u308b\u5f71\u97ff\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c29\u56de\u65e5\u672c\u304c\u3093\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025,7.2-4\uff08\u672d\u5e4c\uff09\u30dd\u30b9\u30bf\u30fc\u8cde\u53d7\u8cde<\/span><\/li>\n
  17. \u8d64\u5800\u6c38\u502b\u9999, Yu L, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u00a0 \u5f69, \u5bae\u672c\u90c1\u4e5f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aPorphyromonas gingivalis\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u9593\u63a5\u7740\u306e\u4f4e\u4e0b\u3092\u4ecb\u3057\u305f\u816b\u760d\u8ee2\u79fb\u8a98\u5c0e, \u53e3\u6f14, \u7b2c34\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2025.6.20\uff08\u6de1\u8def\uff09<\/span><\/li>\n
  18. \u5b97\u7247\u52c7\u53f2\uff0c\u677e\u7530\u00a0 \u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5bae\u672c\u90c1\u4e5f\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u8840\u7ba1\u5185\u76ae\u306b\u5bfe\u3059\u308b\u4f5c\u7528\u306b\u7740\u76ee\u3057\u305f\u03b2\u906e\u65ad\u85ac\u306e\u304c\u3093\u8ee2\u79fb\u306b\u5bfe\u3059\u308b\u5f71\u97ff\u306e\u691c\u8a0e, \u53e3\u6f14, \u7b2c34\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2025.6.20\uff08\u6de1\u8def\uff09<\/span><\/li>\n
  19. \u8d64\u5800\u6c38\u502b\u9999, Yu L, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u00a0 \u5f69, \u5bae\u672c\u90c1\u4e5f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aPorphyromonas gingivalis\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u9593\u63a5\u7740\u306e\u4f4e\u4e0b\u3092\u4ecb\u3057\u305f\u816b\u760d\u8ee2\u79fb\u8a98\u5c0e, \u53e3\u6f14, \u7b2c63\u56de\u3000\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u5730\u65b9\u90e8\u4f1a, \u7b2c51\u56de\u3000\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2025.5.31\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
  20. \u5b97\u7247\u52c7\u53f2\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5bae\u672c\u90c1\u4e5f\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u8840\u7ba1\u5185\u76ae\u3078\u306e\u4f5c\u7528\u3092\u4ecb\u3057\u305f\u03b2\u906e\u65ad\u85ac\u306e\u304c\u3093\u8ee2\u79fb\u306b\u5bfe\u3059\u308b\u5f71\u97ff\u306e\u691c\u8a0e, \u53e3\u6f14, \u7b2c63\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u5730\u65b9\u90e8\u4f1a, 2025.5.31\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
  21. \u8d64\u5800\u6c38\u502b\u9999, Yu L, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u00a0 \u5f69, \u9577\u8c37\u90e8\u6643, \u5bae\u672c\u90c1\u4e5f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: Porphyromonas gingivalis\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u9593\u63a5\u7740\u306e\u4f4e\u4e0b\u3092\u4ecb\u3057\u305f\u816b\u760d\u8ee2\u79fb\u8a98\u5c0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c79\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.5.17\uff08\u677e\u672c\uff09<\/span><\/li>\n
  22. \u5b97\u7247\u52c7\u53f2\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5bae\u672c\u90c1\u4e5f\uff0c\u6a0b\u7530\u4eac\u5b50\uff1a\u30b9\u30c8\u30ec\u30b9\u72b6\u6cc1\u4e0b\u306e\u8840\u7ba1\u75c5\u614b\u3068\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u03b2\u906e\u65ad\u85ac\u306e\u4f5c\u7528\u6a5f\u5e8f\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, \u7b2c79\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2025.5.17\uff08\u677e\u672c\uff09<\/span><\/li>\n
  23. \u685c\u4e95\u512a\u5f25\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u85e4\u5ca1\u5bb9\u4e00\u6717\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6b66\u7530\u3000\u907c\uff0c\u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50\uff0c\u6a0b\u7530\u6cf0\u6d69, \u6fa4\u3000\u6d0b\u6587, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u52a0\u9f62\u306b\u4f34\u3046\u8840\u7ba1\u5185\u76ae\u7d30\u80deSARS-CoV-2\u611f\u67d3\u5897\u5f37\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u6790, \u53e3\u6f14, \u7b2c114\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2025.4.19\uff08\u4ed9\u53f0\uff09<\/span><\/li>\n
  24. \u677e\u7530\u3000\u5f69, \u9593\u77f3\u5948\u6e56, Yu Li, \u8d64\u5800\u6c38\u502b\u9999, \u624b\u4ee3\u6728\u5b5d\u4ec1, \u7531\u826f\u5468\u5b50, \u8c37\u5d8b\u6210\u6a39, \u6a0b\u7530\u6cf0\u6d69, \u897f\u539f\u5e83\u53f2, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u30b2\u30ce\u30e0\u5909\u7570\u306e\u691c\u51fa, \u53e3\u6f14, \u7b2c114\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2025.4.18\uff08\u4ed9\u53f0\uff09<\/span><\/li>\n
  25. \u5b97\u7247\u52c7\u53f2\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5bae\u672c\u90c1\u4e5f\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u03b2\u906e\u65ad\u85ac\u306e\u8840\u7ba1\u5185\u76ae\u3078\u306e\u4f5c\u7528\u3092\u4ecb\u3057\u305f\u304c\u3093\u8ee2\u79fb\u306b\u4e0e\u3048\u308b\u5f71\u97ff\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c114\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2025.4.17\uff08\u4ed9\u53f0\uff09<\/span><\/li>\n<\/ol>\n

    2024<\/strong><\/p>\n

      \n
    1. \u685c\u4e95\u512a\u5f25,\u9593\u77f3\u5948\u6e56,\u85e4\u5ca1\u5bb9\u4e00\u6717,\u5927\u5834\u96c4\u4ecb,\u6b66\u7530\u907c,\u4f50\u3005\u6728\u9053\u4ec1,\u5927\u5834\u9756\u5b50,\u6a0b\u7530\u6cf0\u6d69,\u6fa4\u6d0b\u6587,\u6a0b\u7530\u4eac\u5b50\uff1a\u52a0\u9f62\u306b\u4f34\u3046\u8840\u7ba1\u5185\u76ae\u7d30\u80deSARS-CoV-2\u611f\u67d3\u5897\u5f37\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u6790,\u7b2c32\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2024.12.7\uff08\u6771\u4eac\uff09<\/li>\n
    2. Jia Zi,\u9593\u77f3\u5948\u6e56,\u677e\u7530\u5f69,\u5343\u7530\u5065\u535a,\u4e2d\u5cf6\u5b5d\u5e73,\u6a0b\u7530\u6cf0\u6d69,\u5c0f\u5ddd\u7f8e\u9999\u5b50,\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aAngiogenic inhibitor pre-administration improves the therapeutic effects of Near-infrared photoimmunotherapy, \u7b2c57\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2024.10.12\uff08\u65ed\u5ddd\uff09<\/li>\n
    3. \u8d64\u5800\u6c38\u502b\u9999, YuLi, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u5f69, \u9577\u8c37\u90e8\u6643, \u5bae\u672c\u90c1\u4e5f,\u00a0\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aPorphyromonas gingivalis\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f62\u8cea\u5909\u5316\u306f\uff0c\u8840\u7ba1\u900f\u904e\u6027\u4ea2\u9032\u3092\u8a98\u5c0e\u3057\u816b\u760d\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b, \u7b2c57\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2024.10.12\uff08\u65ed\u5ddd\uff09<\/li>\n
    4. \u5b97\u7247\u52c7\u53f2, \u677e\u7530\u5f69, \u9593\u77f3\u5948\u6e56, \u5bae\u672c\u90c1\u4e5f, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u03b2\u906e\u65ad\u85ac\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3078\u306e\u4f5c\u7528\u89e3\u6790\u3068\u304c\u3093\u8ee2\u79fb\u3078\u306e\u5f71\u97ff, \u7b2c57\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2024.10.12\uff08\u65ed\u5ddd\uff09<\/li>\n
    5. Yu L, Hong Y, Lin L, Maishi N, Matsuda A, Dawood RIH, Sun W, Hida Y, Sato M\uff0cSato Y, Hida K: Biglycan in TEC promotes cancer-associated thrombosis formation, \u7b2c129\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a, 2024.9.14\uff08\u672d\u5e4c\uff09<\/li>\n
    6. \u6d2a\u8aed\u7469\uff0c\u4f59\u9e97 \uff0c\u9ad8\u6a4b\u90c1\u5b50 \uff0c\u9593\u77f3\u5948\u6e56 \uff0c\u677e\u7530\u3000\u5f69 \uff0c\u6a0b\u7530\u6cf0\u6d69 \uff0c\u5bae\u672c\u90c1\u4e5f \uff0c \u6a0b\u7530\u4eac\u5b50<\/u>: Comparison miRNA in tumor endothelial cells of high and low metastatic tumors, \u7b2c129\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a, 2024.9.14\uff08\u672d\u5e4c\uff09<\/li>\n
    7. \u4f50\u85e4\u7950\u9ebb\uff0c\u685c\u4e95\u512a\u5f25 \uff0c\u624b\u4ee3\u6728\u5b5d\u4ec1 \uff0c\u9593\u77f3\u5948\u6e56 \uff0c\u4f59\u9e97 \uff0c\u677e\u7530\u5f69 \uff0c\u698a\u539f\u7d14 \uff0c \u4eca\u91ce\u3000\u54f2 \uff0c\u6a0b\u7530\u6cf0\u6d69 \uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5316\u5b66\u7642\u6cd5\u8a98\u5c0e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u8001\u5316\u304c\u3082\u305f\u3089\u3059\u514d\u75ab\u5fae\u5c0f\u74b0\u5883\u3078\u306e\u5f71\u97ff, \u7b2c129\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a, 2024.9.14\uff08\u672d\u5e4c\uff09<\/li>\n
    8. \u685c\u4e95\u512a\u5f25, \u9593\u77f3\u5948\u6e56\uff0c\u85e4\u5ca1\u5bb9\u4e00\u6717, \u5927\u5834\u96c4\u4ecb\uff0c\u6b66\u7530\u3000\u907c\uff0c\u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50\uff0c\u6a0b\u7530\u6cf0\u6d69,\u3000\u6fa4\u3000\u6d0b\u6587\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u52a0\u9f62\u306b\u4f34\u3046\u8840\u7ba1\u5185\u76ae\u7d30\u80de SARS-CoV-2 \u611f\u67d3\u5897\u5f37\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u6790, \u53e3\u6f14, \u7b2c19\u56de\u5148\u7aef\u6b6f\u5b66\u30b9\u30af\u30fc\u30eb2024, 2024.8.23\uff08\u6771\u4eac\uff09\u512a\u79c0\u8cde\u53d7\u8cde<\/span><\/li>\n
    9. \u6a0b\u7530\u4eac\u5b50, \u9593\u77f3\u5948\u6e56, \u685c\u4e95\u512a\u5f25, \u4f0a\u85e4 \u822a, \u624b\u4ee3\u6728\u5b5d\u4ec1, \u6b66\u7530 \u907c, \u6a0b\u7530\u6cf0\u6d69, \u7a4d\u7530\u5353\u4e5f,\u677e\u7530 \u5f69, \u5c04\u5834\u667a\u5927, \u5185\u85e4\u5c1a\u9053, \u9ad8\u5c71\u548c\u96c4, \u4f50\u3005\u6728\u9053\u4ec1, \u5927\u5834\u9756\u5b50, \u6fa4\u3000\u6d0b\u6587:
      \nSARS-CoV-2\u611f\u67d3\u9577\u671f\u7d4c\u904e\u5f8c\u306e\u75c5\u614b\u306b\u53ca\u307c\u3059\u52a0\u9f62\u306e\u5f71\u97ff, \u53e3\u6f14, \u7b2c2\u56de\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u7814\u7a76\u96c6\u4f1a, 2024.8.4\uff08\u6771\u4eac\uff09<\/li>\n
    10. \u685c\u4e95\u512a\u5f25, \u9593\u77f3\u5948\u6e56, \u85e4\u5ca1\u5bb9\u4e00\u6717, \u5927\u5834\u96c4\u4ecb, \u4f50\u3005\u6728\u9053\u4ec1, \u5927\u5834\u9756\u5b50, \u6a0b\u7530\u6cf0\u6d69, \u6fa4 \u6d0b\u6587, \u6a0b\u7530\u4eac\u5b50: \u8840\u7ba1\u306e\u52a0\u9f62\u5909\u5316\u304c\u3082\u305f\u3089\u3059SARS-CoV-2\u53d6\u308a\u8fbc\u307f\u5897\u52a0\u306e\u30e1\u30ab\u30cb\u30ba\u30e0,\u53e3\u6f14, \u7b2c2\u56de\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u7814\u7a76\u96c6\u4f1a, 2024.8.2-2024.8.4\uff08\u6771\u4eac\uff09<\/li>\n
    11. \u677e\u7530\u3000\u5f69\uff0c\u5317\u6751\u54f2\u4e5f\uff0c\u5409\u5ddd\u548c\u4eba\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u4eac\u5b50: \u820c\u4e0b\u817a\u306b\u767a\u751f\u3057\u305f\u7a00\u306a\u817a\u623f\u7d30\u80de\u764c\u306e\u4e00\u4f8b,\u30dd\u30b9\u30bf\u30fc, \u7b2c35\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a,2024,7,30\uff0d2024.8.1\uff08\u65b0\u6f5f\uff09<\/li>\n
    12. \u685c\u4e95\u512a\u5f25\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530\u3000\u5f69\uff0c\u6b66\u7530\u3000\u907c\uff0c\u4f0a\u85e4\u3000\u822a\uff0c\u6a0b\u7530\u4eac\u5b50: \u52a0\u9f62\u306b\u4f34\u3046\u8840\u7ba1\u5185\u76ae\u7d30\u80deSARS-CoV-2\u611f\u67d3\u5897\u5f37\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc. \u7b2c35\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2024,7,30\uff0d2024.8.1\uff08\u65b0\u6f5f\uff09\u512a\u79c0\u30dd\u30b9\u30bf\u30fc\u8cde\u53d7\u8cde<\/li>\n
    13. \u4f59 \u9e97, \u9593\u77f3 \u5948\u6e56, \u677e\u7530 \u5f69, <\/span>\u6a0b\u7530 \u4eac\u5b50<\/span>: \u8840\u7ba1\u708e\u75c7\u306b\u3088\u308b\u304c\u3093\u306e\u8ee2\u79fb\u4fc3\u9032, \u53e3\u6f14, \u7b2c78\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a. 2024.7.19-21(\u6771\u4eac)<\/span><\/li>\n
    14. Li Yu: Vascular inflammation in inducing cancer-related thrombosis, \u53e3\u6f14, \u7b2c 6 \u56de \u53e3\u8154\u533b\u79d1\u5b66\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\u7814\u7a76\u4f1a, 2024.5.18\uff08\u672d\u5e4c\uff09<\/li>\n<\/ol>\n

      2023<\/strong><\/p>\n

        \n
      1. \u677e\u7530\u3000\u5f69. \u4efb\u3000\u5b50\u9a4d, \u65b0\u5c71\u3000\u5b97, \u9593\u77f3\u5948\u6e56, \u5927\u5ee3\u6d0b\u4e00, \u4e0a\u7530\u502b\u5f18, \u6a0b\u7530\u4eac\u5b50: \u53e3\u8154\u764c\u767a\u304c\u3093\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u306e\u89e3\u6790, \u53e3\u6f14, \u7b2c113\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2024.3.28,\uff08\u540d\u53e4\u5c4b\uff09<\/span><\/li>\n
      2. \u685c\u4e95\u512a\u5f25\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u85e4\u5ca1\u5bb9\u4e00\u6717\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6b66\u7530\u907c\uff0c\u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50 \uff0c\u6a0b\u7530\u6cf0\u6d69,\u3000\u6fa4\u3000\u6d0b\u6587\uff0c\u6a0b\u7530\u4eac\u5b50: \u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bSARS-CoV-2\u4fb5\u5165\u6a5f\u69cb\u306e\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, \u7b2c113\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2024.3.28,\uff08\u540d\u53e4\u5c4b\uff09<\/span><\/li>\n
      3. Yu L, Hong Y, Maishi N, Matsuda A, Hida Y, Hasebe A, Kitagawa Y, <\/span>Hida K<\/span>: Oral bacterium streptococcus mutans promotes tumor metastasis via thrombosis formation, Oral, <\/span>\u7b2c31\u56de \u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.12.9-10\uff08\u795e\u6238\uff09<\/span><\/li>\n
      4. \u685c\u4e95\u512a\u5f25\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u85e4\u5ca1\u5bb9\u4e00\u6717\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6b66\u7530\u3000\u907c\uff0c\u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50\uff0c\u6a0b\u7530\u6cf0\u6d69,\u3000\u6fa4\u3000\u6d0b\u6587\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bSARS-CoV-2\u4fb5\u5165\u6a5f\u69cb\u306e\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, <\/span>\u7b2c31\u56de \u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.12.9-10\uff08\u795e\u6238\uff09<\/span><\/li>\n
      5. Ren Zixiao<\/span>, Matsuda A, Maishi N, Niiyama T,\u00a0 Ohiro Y, <\/span>Hida K<\/span>: The mechanism of neogenesis and development of Tumor-associated HEV, Oral, \u7b2c127\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a, 2023.11.11\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
      6. Hong Y, Yu L, Takahashi I,\u00a0 Maishi N, Sakurai Y, Hida Y, Yoshioka Y, Ochiya T, Kitagawa Y, Hida K: Comparison miRNA in extracellular vesicles secreted from tumor endothelial cells between high and low metastatic tumors, \u30dd\u30b9\u30bf\u30fc, \u7b2c10\u56de \u65e5\u672c\u7d30\u80de\u5916\u5c0f\u80de\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.10.24\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
      7. \u685c\u4e95\u512a\u5f25, \u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530\u00a0 \u5f69\uff0c\u5409\u5ca1 \u7950\u4eae\uff0c\u6b66\u7530\u00a0 \u907c\uff0c\u7a4d\u7530\u5353\u4e5f\uff0c\u4f0a\u85e4\u00a0 \u822a\uff0c\u624b\u4ee3\u6728 \u5b5d\u4ec1, \u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50\uff0c\u4f50\u85e4\u5f70\u5f66\uff0c\u9ce5\u7fbd\u664b\u8f14\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6fa4\u00a0 \u6d0b\u6587\uff0c\u57ce\u6238\u5e79\u592a\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50: \u52a0\u9f62\u306b\u4f34\u3046\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u91cd\u75c7\u5316\u306b\u304a\u3051\u308bSARS-CoV-2\u611f\u67d3\u8840\u7ba1\u5185\u76ae\u7d30\u80deEVs\u306e\u5f79\u5272, \u30dd\u30b9\u30bf\u30fc, \u7b2c10\u56de \u65e5\u672c\u7d30\u80de\u5916\u5c0f\u80de\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.10.23\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
      8. \u624b\u4ee3\u6728\u5b5d\u4ec1, \u6b66\u7530\u3000\u907c\uff0c\u8429\u91ce\u88d5\u592a, \u4f0a\u85e4\u3000\u822a\uff0c\u685c\u4e95\u512a\u5f25\uff0c\u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530\u3000\u5f69\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u5cf6 \u79c0\u5409,\u00a0 \u6fa4\u3000\u6d0b\u6587\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: COVID-19\u91cd\u75c7\u5316\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u80ba\u6a19\u7684Celastrol-GALA-LNP\u306e\u52b9\u679c\u691c\u8a0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c9\u56de \u5317\u5927\u30fb\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0, 2023.10.11\uff08\u672d\u5e4c\uff09<\/li>\n
      9. Ren Zixiao, Aya Matsuda, Nako Maishi, Takashi Niiyama, Yoichi Ohiro, Kyoko Hida<\/u>: The mechanism of neogenesis and development of Tumor-associated HEV, Poster, \u7b2c9\u56de \u5317\u5927\u30fb\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0, 2023.10.11\uff08\u672d\u5e4c\uff09<\/li>\n
      10. Yuying Hong, Li Yu, Ikuko Takahashi, Nako Maishi,\u00a0 Yuya Sakurai, Yasuhiro Hida, Yusuke Yoshioka, Takahiro Ochiya, Yoshimasa Kitagawa, Kyoko Hida<\/u>, Effects of miRNA in extracellular vesicles derived from tumor endothelial cells promote tumor microenvironment formation and metastasis, Poster, \u7b2c9\u56de \u5317\u5927\u30fb\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0, 2023.10.11\uff08\u672d\u5e4c\uff09<\/li>\n
      11. Zi Jia, Maishi N , Takekawa H, Matsuda A , Nakade T, Nakamura T, Harashima H, Hida Y, Hida K<\/u>: Targeting tumor endothelial cells by EGCG causes antiinflammatory and anti-thrombotic effects,\u00a0 Poster, The 82nd annual meeting of the Japanese Cancer Association. 2023. 9. 22, Yokohama<\/li>\n
      12. Li Yu, Maishi N, Yuying Hong, Matsuda A, Hida Y, Hasebe A, Nam JM, Hida K<\/u>: \u201cThe oral bacterium Streptococcus mutans promotes tumor metastasis by inducing thrombosis\u201d, Poster, The 82nd annual meeting of the Japanese Cancer Association. 2023. 9. 21, Yokohama<\/li>\n
      13. \u685c\u4e95\u512a\u5f25\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530\u5f69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>; \u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bSARS-CoV-2\u4fb5\u5165\u6a5f\u69cb\u306e\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, \u7b2c65\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2023.9.16\uff08\u6771\u4eac\uff09<\/li>\n
      14. \u4f0a\u85e4 \u822a\uff0c\u6b66\u7530 \u907c\uff0c\u7a4d\u7530 \u5353\u4e5f\uff0c\u624b\u4ee3\u6728 \u5b5d\u4ec1\uff0c\u685c\u4e95 \u512a\u5f25\uff0c\u4f50\u3005\u6728 \u9053\u4ec1\uff0c\u5927\u5834 \u9756\u5b50\uff0c\u9593\u77f3 \u5948\u6e56\uff0c\u677e\u7530 \u5f69\uff0c\u4f50\u85e4 \u5f70\u5f66\uff0c\u9ce5\u7fbd\u3000\u664b\u8f14\uff0c\u6a0b\u7530 \u6cf0\u6d69\uff0c\u5927\u5ee3 \u6d0b\u4e00\uff0c\u6fa4 \u6d0b\u6587\uff0c\u6a0b\u7530 \u4eac\u5b50<\/u>: SARS-CoV-2\u306f\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306eItgb3\u3092\u8a98\u5c0e\u3057\uff0c\u8840\u6813\u5f62\u6210\u3092\u4fc3\u9032\u3059\u308b, \u53e3\u6f14, \u7b2c 56 \u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2023.9.16\uff08\u672d\u5e4c\uff09<\/li>\n
      15. \u4e2d\u897f\u4fca\u5e0c, \u6b66\u7530 \u907c, \u8429\u91ce\u88d5\u592a, \u9593\u77f3\u5948\u6e56, \u7a4d\u7530\u5353\u4e5f, \u7af9\u5ddd\u82f1\u8f1d, \u6a0b\u7530\u6cf0\u6d69, \u4f0a\u85e4 \u822a, \u624b\u4ee3\u6728\u5b5d\u4ec1, \u685c\u4e95\u512a\u5f25, \u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50\uff0c\u677e\u7530 \u5f69, \u539f\u5cf6\u79c0\u5409, \u6fa4 \u6d0b\u6587, \u6a0b\u7530\u4eac\u5b50: \u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u8304\u91cd\u75c7\u5316\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u3092\u7528\u3044\u305fCelastrol\u306e\u52b9\u679c\u691c\u8a3c, \u53e3\u6f14, \u7b2c 56 \u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2023.9.16\uff08\u672d\u5e4c\uff09<\/li>\n
      16. \u9593\u77f3\u5948\u6e56: \u7b2c 3 4 \u56de \u65e5 \u672c \u81e8 \u5e8a \u53e3 \u8154 \u75c5 \u7406 \u5b66 \u4f1a \u7dcf \u4f1a \u30fb \u5b66 \u8853 \u5927 \u4f1a \u7b2c 1 5 \u56de \u82e5 \u624b \u306e \u96c6\u3044, \u304c\u3093\u7d30\u80de\uff0d\u8840\u7ba1\u5185\u76ae\u7d30\u80deCluster\u5f62\u6210\u306b\u3088\u308b\u304c\u3093\u60aa\u6027\u5316\u4fc3\u9032, \u53e3\u6f14, \u7b2c34\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2023.8.24\uff08\u5927\u962a\u5e9c\u5439\u7530\u5e02\uff09<\/span><\/li>\n
      17. \u6a0b\u7530\u4eac\u5b50<\/span>\uff0c\u6b66\u7530\u3000\u907c\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u4f0a\u85e4\u3000\u822a\uff0c\u677e\u7530\u3000\u5f69: SARS-CoV-2\u611f\u67d3\u80ba\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u75c5\u614b\u306b\u304a\u3051\u308b\u52a0\u9f62\u306e\u5f71\u97ff, \u30dd\u30b9\u30bf\u30fc, \u7b2c34\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2023.8.24-26\uff08\u5927\u962a\u5e9c\u5439\u7530\u5e02\uff09<\/span><\/li>\n
      18. \u9593\u77f3\u5948\u6e56\uff0c\u8d64\u5800\u6c38\u502b\u9999\uff0c\u677e\u7530 \u5f69\uff0c\u6b66\u7530\u3000\u907c\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u53e3\u8154\u5185\u7d30\u83ccStreptococcus mutans\u306f\uff0c\u8840\u7ba1\u708e\u75c7\u3092\u8a98\u5c0e\u3057\u3066\u304c\u3093\u306e\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b, \u30dd\u30b9\u30bf\u30fc, \u7b2c34\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2023.8.25\uff08\u5927\u962a\u5e9c\u5439\u7530\u5e02\uff09<\/span><\/li>\n
      19. \u677e\u7530\u3000\u5f69\uff0c\u5317\u6751\u54f2\u4e5f\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5742\u7530\u5065\u4e00\u90ce\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>; \u7c98\u8868\u76ae\u764c\u306e\u518d\u767a\u3068\u7591\u308f\u308c\u305fClear cell carcinoma\uff08CCC\uff09\u306e\u4e00\u4f8b, \u30dd\u30b9\u30bf\u30fc, \u7b2c34\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2023.8.24-26\uff08\u5927\u962a\u5e9c\u5439\u7530\u5e02\uff09<\/span><\/li>\n
      20. \u4f0a\u85e4\u3000\u822a, \u6b66\u7530\u3000\u907c, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u5927\u5ee3\u6d0b\u4e00, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: <\/span>\u00a0<\/span>SARS-CoV-2\u306f\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306eItgb3\u3092\u8a98\u5c0e\u3057\uff0c\u8840\u6813\u5f62\u6210\u3092\u4fc3\u9032\u3059\u308b, \u30dd\u30b9\u30bf\u30fc, \u7b2c34\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2023.8.24-26\uff08\u5927\u962a\u5e9c\u5439\u7530\u5e02\uff09<\/span><\/li>\n
      21. \u6a0b\u7530\u4eac\u5b50<\/span>, \u7a4d\u7530\u5353\u4e5f, \u6b66\u7530\u3000\u907c\uff0c\u9593\u77f3\u5948\u6e56,\u3000\u4f0a\u85e4\u3000\u822a, \u624b\u4ee3\u6728\u5b5d\u4ec1,\u3000\u685c\u4e95\u512a\u5f25, \u4f50\u3005\u6728\u9053\u4ec1, \u5927\u5834\u9756\u5b50\uff0c\u9ce5\u7fbd\u771f\u8f14\uff0c\u4f50\u85e4\u5f70\u5f66\uff0c\u677e\u7530\u3000\u5f69\uff0c\u98ef\u6751\u5fe0\u6d69\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6fa4\u3000\u6d0b\u6587: \u8001\u5316\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3092\u7528\u3044\u305f SARS-CoV-2 \u611f\u67d3\u91cd\u75c7\u5316\u95a2\u9023\u907a\u4f1d\u5b50\u306e\u691c\u8a0e, \u7b2c19\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9. \u30dd\u30b9\u30bf\u30fc, 2023.8.4-6\uff08\u51fd\u9928\uff09<\/span><\/li>\n
      22. \u624b\u4ee3\u6728\u5b5d\u4ec1, \u7a4d\u7530\u5353\u4e5f, \u6b66\u7530\u3000\u907c\uff0c\u4f0a\u85e4\u3000\u822a, \u685c\u4e95\u512a\u5f25, \u5927\u5834\u9756\u5b50\uff0c\u4f50\u3005\u6728\u9053\u4ec1\uff0c\u9ce5\u7fbd\u771f\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530\u3000\u5f69\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6fa4\u3000\u6d0b\u6587\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u8001\u5316\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3092\u7528\u3044\u305f SARS-CoV-2 \u611f\u67d3\u91cd\u75c7\u5316\u95a2\u9023\u907a\u4f1d\u5b50\u306e\u691c\u8a0e, \u7b2c19\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9. \u30dd\u30b9\u30bf\u30fc, 2023.8.4-6\uff08\u51fd\u9928\uff09<\/span><\/li>\n
      23. Jia Zi , \u9593\u77f3\u5948\u6e56 , \u7af9\u5ddd \u82f1\u8f1d , \u677e\u7530\u3000\u5f69 , \u4e2d\u51fa \u6cf0\u8aa0 , \u4e2d\u6751 \u5b5d\u53f8 , \u539f\u5cf6 \u79c0\u5409 , \u6a0b\u7530\u6cf0\u6d69, <\/span>\u6a0b\u7530 \u4eac\u5b50<\/span>: \u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3092\u6a19\u7684\u3068\u3057\u305fEGCG\u6295\u4e0e\u306b\u3088\u308b\u6297\u708e\u75c7\u30fb\u6297\u8840\u6813\u52b9\u679c, \u30dd\u30b9\u30bf\u30fc, \u7b2c32\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2023.7.20\uff08\u4ed9\u53f0\uff09<\/span><\/li>\n
      24. Yu Li, Maishi N, Akahori E, Hasebe A, Takeda R, Matsuda A, Hida Y,<\/span> Kitagawa Y, <\/span>\u00a0Hida K<\/span>: \u53e3\u8154\u5e38\u5728\u83cc Streptococcus mutans \u304c\u5f15\u304d\u8d77\u3053\u3059\u8840\u7ba1\u708e\u75c7\u306f\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b, \u30dd\u30b9\u30bf\u30fc, \u7b2c32\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2023.7.20\uff08\u4ed9\u53f0\uff09<\/span><\/li>\n
      25. Yu Li, \u9593\u77f3\u5948\u6e56, \u8d64\u5800\u6c38\u502b\u9999, \u9577\u8c37\u90e8\u6643, \u6b66\u7530 \u00a0 \u907c, \u677e\u7530\u3000\u5f69, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: The oral bacterium Streptococcus mutans promotes tumor metastasis by inducing vascular inflammation, \u7b2c40\u56de\u5206\u5b50\u75c5\u7406\u5b66\u7814\u7a76\u4f1a\u30af\u30e9\u30fc\u30af\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0, 2023.7.14\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
      26. \u6a0b\u7530\u4eac\u5b50<\/span>\uff1aSARS\u2010CoV-2\u611f\u67d3\u30de\u30a6\u30b9\u3092\u7528\u3044\u305f\u80ba\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u75c5\u614b\u89e3\u6790, \u7b2c1\u56de\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a3\u30eb\u30b9\u7814\u7a76\u96c6\u4f1a, 2023.6.8\uff08\u6771\u4eac\uff09<\/span><\/li>\n
      27. \u9ad8\u6a4b\u8ce2\u591a, \u683c\u53e3\u3000\u6e09, \u6b66\u7530\u53e1\u53f8, \u7bad\u539f\u5143\u57fa, \u912d\u3000\u6f22\u5fe0, \u677e\u7530\u3000\u5f69, \u9593\u77f3\u5948\u6e56, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>, \u677e\u4e0b\u548c\u88d5, \u8db3\u5229\u96c4\u4e00, \u5927\u5ee3\u6d0b\u4e00: \u5480\u56bc\u7b4b\u8171\u30fb\u8171\u819c\u904e\u5f62\u6210\u75c7\u306b\u4f34\u3046\u4e0b\u984e\u9aa8\u306e\u5909\u5f62\u306b\u5bfe\u3057\u30ac\u30a4\u30c9\u30b5\u30fc\u30b8\u30a7\u30ea\u30fc\u3092\u7528\u3044\u3066\u6cbb\u7642\u3057\u305f1\u4f8b, \u53e3\u6f14<\/span>, \u7b2c49\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u5b66\u8853\u96c6\u4f1a, \u7b2c61\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u5730\u65b9\u90e8\u4f1a, 2023.5.20\uff08\u5ca1\u5c71\uff09<\/span><\/li>\n
      28. Yu Li, \u9593\u77f3\u5948\u6e56, \u8d64\u5800\u6c38\u502b\u9999, \u6b66\u7530\u3000\u907c, \u677e\u7530\u3000\u5f69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: Streptococcus mutans promotes tumor metastasis by inducing vascular inflammation, \u30dd\u30b9\u30bf\u30fc, \u7b2c77\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.5.12\uff08\u5ca1\u5c71\uff09<\/span><\/li>\n
      29. \u6b66\u7530\u3000\u907c, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u6d17\u53e3\u6db2\u4e2d\u6bba\u83cc\u6210\u5206\u30bb\u30c1\u30eb\u30d4\u30ea\u30b8\u30cb\u30a6\u30e0\u5869\u5316\u7269\u6c34\u548c\u7269\u306eSARS-CoV-2\u306b\u5bfe\u3059\u308b\u52b9\u679c, \u30dd\u30b9\u30bf\u30fc, \u7b2c77\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.5.12\uff08\u5ca1\u5c71\uff09<\/span><\/li>\n
      30. \u5343\u7530\u5065\u535a, \u677e\u7530\u3000\u5f69, \u9593\u77f3\u5948\u6e56, \u5927\u5ee3\u6d0b\u4e00, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u8fd1\u8d64\u5916\u7dda\u5149\u514d\u75ab\u7642\u6cd5\u306b\u3088\u308b\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306e\u5909\u5316\u306e\u75c5\u7406\u7d44\u7e54\u5b66\u7684\u89e3\u6790, \u53e3\u6f14, \u7b2c77\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2023.5.12\uff08\u5ca1\u5c71\uff09<\/span><\/li>\n
      31. \u9593\u77f3\u5948\u6e56, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u304c\u3093\u7d30\u80de\uff0d\u8840\u7ba1\u5185\u88ab\u7d30\u80deCluster\u5f62\u6210\u306b\u3088\u308b\u304c\u3093\u60aa\u6027\u5316\u4fc3\u9032, \u53e3\u6f14, \u7b2c\uff15\u56de\u53e3\u8154\u533b\u79d1\u5b66\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\u7814\u7a76\u4f1a, 2023.4.16\uff08\u65b0\u6f5f\uff09<\/span><\/li>\n
      32. \u677e\u7530\u3000\u5f69,\u00a0 \u4efb\u3000\u5b50\u9a4d,\u00a0 \u65b0\u5c71\u3000\u5b97,\u00a0 \u9593\u77f3\u5948\u6e56,\u00a0 \u5927\u5ee3\u6d0b\u4e00, \u4e0a\u7530\u502b\u5f18,<\/span> \u6a0b\u7530\u4eac\u5b50<\/span>: \u764c\u7d44\u7e54\u306b\u5b58\u5728\u3059\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u5f62\u6210\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e, \u53e3\u6f14, \u7b2c112\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2023.4.14\uff08\u4e0b\u95a2\uff09<\/span><\/li>\n<\/ol>\n

        2022<\/strong><\/p>\n

          \n
        1. \u9593\u77f3\u5948\u6e56, \u9ce5\u5c45\u3061\u3055\u307b, \u68ee\u672c\u771f\u5f18, \u677e\u7530\u3000\u5f69, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>; \u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u7d30\u80de\u5916\u5c0f\u80de\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u7372\u5f97\u3068\u304c\u3093\u60aa\u6027\u5316, \u30dd\u30b9\u30bf\u30fc, \u7b2c9\u56de\u65e5\u672c\u7d30\u80de\u5916\u5c0f\u80de\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2022.10.25\uff08\u6771\u4eac\uff09<\/span><\/li>\n
        2. \u7af9\u5ddd\u82f1\u8f1d, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, Alam MT, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: Biglycan\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u5019\u88dc\u85ac\u306e\u691c\u8a0e, \u53e3\u6f14, \u7b2c125\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a, 2022.10.22<\/span><\/li>\n
        3. Jia Z, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u5343\u7530\u5065\u535a, \u4e2d\u5cf6\u5b5d\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u5c0f\u5ddd\u7f8e\u9999\u5b50,<\/span> \u6a0b\u7530\u4eac\u5b50<\/span>; Angiogenic inhibitor pre-administration improves the therapeutic effects of Near-infrared photoimmunotherapy, \u53e3\u6f14, \u7b2c125\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a, 2022.10.22<\/span><\/li>\n
        4. Yu L, \u9593\u77f3\u5948\u6e56, \u8d64\u5800\u6c38\u502b\u9999, \u9577\u8c37\u90e8\u3000\u6643, \u6b66\u7530\u3000\u907c, \u677e\u7530\u3000\u5f69, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: The oral bacterium Streptococcus mutans promotes tumor metastasis by inducing vascular inflammation, \u53e3\u6f14, \u7b2c125\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a, 2022.10.22<\/span><\/li>\n
        5. Yu L, Maishi N, Akahori E, Hasebe A, Mathuda A, Hida Y, Kitagawa Y, Hida K: The oral bacterium Streptococcus mutans promotes tumor metastasis by inducing vascular inflammation\uff08\u53e3\u8154\u7d30\u83cc, Streptococcus mutans\u306f, \u8840\u7ba1\u708e\u75c7\u3092\u8a98\u767a\u3057\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b\uff09, \u30dd\u30b9\u30bf\u30fc, \u7b2c81\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2022.10.1\uff08\u6a2a\u6d5c\uff09<\/span><\/li>\n
        6. \u4f50\u85e4\u5cf0\u5609, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u677e\u7530\u3000\u5f69, \u698a\u539f\u3000\u7d14, \u6a0b\u7530\u4eac\u5b50: Angiogenic inhibitor pre-administration improves the therapeutic effects of immunotherapy\uff08\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u306e\u5148\u884c\u6295\u4e0e\u306f\u514d\u75ab\u7642\u6cd5\u306e\u6cbb\u7642\u52b9\u679c\u3092\u6539\u5584\u3059\u308b\uff09, \u82f1\u8a9e\u53e3\u6f14\u304a\u3088\u3073\u30dd\u30b9\u30bf\u30fc, \u7b2c81\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2022.9.30\uff08\u6a2a\u6d5c\uff09<\/span><\/li>\n
        7. \u83ca\u5730\u3000\u592e, \u9593\u77f3\u5948\u6e56, Li C, \u4f50\u85e4\u5cf0\u5609, \u6a0b\u7530\u6cf0\u6d69, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>: \u4f4e\u7528\u91cf\u7dad\u6301\u6295\u4e0e\u306e\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u306f\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u708e\u75c7\u6027\u5909\u5316\u3092\u6291\u5236\u3059\u308b, \u30dd\u30b9\u30bf\u30fc, \u7b2c81\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2022.9.29\uff08\u6a2a\u6d5c\uff09<\/span><\/li>\n
        8. \u65b0\u5c71\u3000\u5b97, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u6a0b\u7530\u6cf0\u6d69, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>; \u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u9ad8\u5185\u88ab\u6027\u9759\u8108\u306e\u81e8\u5e8a\u7684\u610f\u7fa9\u306b\u3064\u3044\u3066, \u30dd\u30b9\u30bf\u30fc, \u7b2c81\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2022.9.29\uff08\u6a2a\u6d5c\uff09<\/span><\/li>\n
        9. \u9593\u77f3\u5948\u6e56\uff0c\u6b66\u7530\u3000\u907c\uff0c\u677e\u7530\u3000\u5f69\uff0c<\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u6d17\u53e3\u6db2\u4e2d\u6bba\u83cc\u6210\u5206\u30bb\u30c1\u30eb\u30d4\u30ea\u30b8\u30cb\u30a6\u30e0\u5869\u5316\u7269\u6c34\u548c\u7269\u306eSARS-CoV-2\u306b\u5bfe\u3059\u308b\u52b9\u679c, \u30dd\u30b9\u30bf\u30fc, \u7b2c33\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a, 2022. 9.23-24\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        10. Takeda R, Maishi N, Matsuda A, <\/span>Hida K<\/span>\uff1a\u6d17\u53e3\u6db2\u4e2d\u6bba\u83cc\u6210\u5206\u30bb\u30c1\u30eb\u30d4\u30ea\u30b8\u30cb\u30a6\u30e0\u5869\u5316\u7269\u6c34\u548c\u7269\u306eSARS-CoV-2\u306b\u5bfe\u3059\u308b\u52b9\u679c, \u30dd\u30b9\u30bf\u30fc, \u7b2c33\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a, 2022. 9.23-24\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        11. \u6b66\u7530\u3000\u907c, \u9593\u77f3\u5948\u6e56, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aSARS-CoV-2\u611f\u67d3\u30de\u30a6\u30b9\u3092\u7528\u3044\u305f\u80ba\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u91cd\u75c7\u5316\u95a2\u9023\u907a\u4f1d\u5b50\u306e\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, \u7b2c64\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2022.9.18\uff08\u5fb3\u5cf6\uff09<\/span><\/li>\n
        12. \u4f0a\u85e4\u3000\u822a, \u6b66\u7530\u3000\u907c, \u624b\u4ee3\u6728\u5b5d\u4ec1, \u4efb\u3000\u5b50\u9a4d, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u5927\u5ee3\u6d0b\u4e00, \u6a0b\u7530\u6cf0\u6d69, \u6fa4\u3000\u6d0b\u6587, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aSARS-CoV-2\u611f\u67d3\u30de\u30a6\u30b9\u306e\u80ba\u306e\u75c5\u7406\u7d44\u7e54\u5b66\u7684\u89e3\u6790, \u53e3\u6f14, \u7b2c55\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2022.9.17\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        13. \u4f50\u85e4\u5cf0\u5609, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u677e\u7530\u5f69, \u698a\u539f \u7d14, \u4eca\u91ce\u54f2, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u306e\u5148\u884c\u6295\u4e0e\u306b\u3088\u308b\u514d\u75ab\u7642\u6cd5\u306e\u6cbb\u7642\u52b9\u679c\u5897\u5f37, \u53e3\u6f14, \u7b2c55\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2022.9.17\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        14. Yu Li, Maishi N, Akahori E, Hasebe A, Takeda R, Mathuda A, Hida Y, Kitagawa Y, <\/span>Hida K<\/span>: The oral bacterium Streptococcus mutans promotes tumor metastasis by inducing vascular inflammation, \u7b2c17\u56de\u5148\u7aef\u6b6f\u5b66\u30b9\u30af\u30fc\u30eb2022, 2022.8.26-27\uff08\u5fb3\u5cf6\uff09<\/span><\/li>\n
        15. \u7af9\u5ddd\u82f1\u8f1d, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, Alam MT, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aBiglycan\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u5019\u88dc\u85ac\u306e\u691c\u8a0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c18\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9, 2022. 7.29-30\uff08\u4ed9\u53f0\uff09<\/span><\/li>\n
        16. \u5343\u7530\u5065\u535a, \u677e\u7530 \u5f69, \u9593\u77f3\u5948\u6e56, \u4f50\u85e4\u5cf0\u5609, Jia Zi, \u4e2d\u5cf6\u5b5d\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u5c0f\u5ddd\u7f8e\u9999\u5b50, \u5927\u5ee3\u6d0b\u4e00, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u8fd1\u8d64\u5916\u5149\u514d\u75ab\u7642\u6cd5\u306b\u3088\u308b\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306e\u75c5\u7406\u7d44\u7e54\u5b66\u7684\u5909\u5316, \u30dd\u30b9\u30bf\u30fc, \u7b2c18\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9, 2022. 7.29-30\uff08\u4ed9\u53f0\uff09<\/span><\/li>\n
        17. \u52a0\u85e4\u6cf0\u53f2, \u5742\u7530\u5065\u4e00\u90ce, \u677f\u57a3\u7adc\u6a39, \u4f50\u85e4\u3000\u6df3, \u677e\u7530\u3000\u5f69, \u4e2d\u6751\u88d5\u4ecb, \u5317\u5ddd\u3000\u5584\u653f\uff1a\u5c0f\u5150\u306b\u751f\u3058\u305f\u30a8\u30ca\u30e1\u30eb\u4e0a\u76ae\u7dda\u7dad\u6b6f\u7259\u816b\u306e1\u4f8b, \u53e3\u6f14, \u7b2c48\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2022.7.10\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        18. \u5742\u7530\u5065\u4e00\u90ce, \u4f50\u85e4\u3000\u660e, \u677f\u57a3\u7adc\u6a39, \u4e2d\u6751\u88d5\u4ecb, \u677e\u7530\u3000\u5f69, \u5927\u8cc0\u5247\u5b5d, \u4f50\u85e4\u3000\u6df3,\u5317\u5ddd\u5584\u653f:<\/span> \u6b6f\u8089\u306b\u751f\u3058\u305f\u53e3\u8154\u9854\u9762\u8089\u82bd\u816b\u75c7\u306e3\u4f8b, \u53e3\u6f14, \u7b2c60\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u5730\u65b9\u90e8\u4f1a, 2022.7.10\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        19. Li YU, Nako MAISHI, Erika AKAHORI, Aya MATSUDA, Yoshimasa KITAGAWA, <\/span>Kyoko HIDA<\/span>:<\/span> Streptococcus mutans promotes tumor metastasis by inducing vascular inflammation, Oral, \u7b2c60\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u5730\u65b9\u90e8\u4f1a, 2022.7.10\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        20. \u4f0a\u85e4\u3000\u822a, \u6b66\u7530\u3000\u907c, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u5927\u5ee3\u6d0b\u4e00, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aSARS-CoV-2\u611f\u67d3\u30de\u30a6\u30b9\u306e\u80ba\u306e\u75c5\u7406\u7d44\u7e54\u5b66\u7684\u89e3\u6790, \u53e3\u6f14, \u7b2c48\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2022.7.10\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        21. \u5343\u7530\u5065\u535a, \u677e\u7530\u3000\u5f69, \u9593\u77f3\u5948\u6e56, Jia Zi , \u5927\u5ee3\u6d0b\u4e00, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1a\u8fd1\u8d64\u5916\u5149\u514d\u75ab\u7642\u6cd5\u306b\u3088\u308b\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306e\u75c5\u7406\u7d44\u7e54\u5b66\u7684\u5909\u5316, \u53e3\u6f14, \u7b2c48\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2022.7.10\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        22. \u6b66\u7530\u3000\u907c, \u4f0a\u85e4\u3000\u822a, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aSARS-CoV-2\u611f\u67d3\u30de\u30a6\u30b9\u3092\u7528\u3044\u305f\u80ba\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u91cd\u75c7\u5316\u95a2\u9023\u907a\u4f1d\u5b50\u306e\u89e3\u6790,<\/span> \u53e3\u6f14,<\/span> \u7b2c60\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u5730\u65b9\u90e8\u4f1a2022.7.10\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        23. \u6751\u4e0a\u5927\u5cb3, \u683c\u53e3\u3000\u6e09, \u9752\u6d77\u54f2\u4e5f, \u4e2d\u91ce\u664b\u592a\u90ce, \u5c0f\u5ddd\u5c1a\u535a, \u8db3\u5229\u96c4\u4e00, \u677e\u7530\u3000\u5f69, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u4eac\u5b50, \u5927\u5ee3\u6d0b\u4e00\uff1a\u56a2\u80de\u6027\u75c5\u5909\u3068\u306e\u9451\u5225\u306b\u82e6\u616e\u3057\u305f\u53e3\u84cb\u4f4e\u60aa\u6027\u5ea6\u7c98\u8868\u76ae\u764c\u306e2\u4f8b, \u53e3\u6f14, \u7b2c48\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2022.7.9\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        24. \u7531\u826f\u5468\u5b50, \u683c\u53e3\u3000\u6e09, \u7be0\u539f\u65e9\u7d00, \u5c0f\u5ddd\u5c1a\u535a, \u8db3\u5229\u96c4\u4e00, \u677e\u7530\u3000\u5f69, \u9593\u77f3\u5948\u6e56, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>, \u5927\u5ee3\u6d0b\u4e00\uff1a\u6210\u4eba\u306e\u5074\u982d\u4e0b\u7aa9\u306b\u751f\u3058\u305f\u786c\u5316\u578b\u6a2a\u7d0b\u7b4b\u8089\u816b\u306e1\u4f8b, \u53e3\u6f14, \u7b2c48\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2022.7.9\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        25. \u5c0f\u5ddd\u5c1a\u535a, \u683c\u53e3\u3000\u6e09, \u8db3\u5229\u3000\u96c4\u4e00, \u6817\u548c\u4ee3, \u7531\u826f\u5468\u5b50, \u7be0\u539f\u65e9\u7d00, \u9593\u77f3\u3000\u5948\u6e56, \u677e\u7530\u3000\u5f69, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>, \u5927\u5ee3\u6d0b\u4e00\uff1a\u96c6\u5b66\u7684\u6cbb\u7642\u306b\u3088\u308a\u5236\u5fa1\u3057\u5f97\u305f\u5207\u9664\u4e0d\u80fd\u53e3\u84cb\u7d21\u9318\u7d30\u80de\u764c\u306e1\u4f8b, \u53e3\u6f14, \u7b2c48\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2022.7.9\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        26. \u7af9\u5ddd\u82f1\u8f1d, \u9593\u77f3\u5948\u6e56, \u677e\u7530 \u5f69, \u5317\u5ddd\u5584\u653f, <\/span>\u6a0b\u7530\u4eac\u5b50<\/span>\uff1aCelastrol\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7279\u7570\u7684\u963b\u5bb3\u4f5c\u7528\u306e\u691c\u8a0e, \u53e3\u6f14, \u7b2c48\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2022.7.9\uff08\u672d\u5e4c\uff09<\/span><\/li>\n
        27. \u9593\u77f3 \u5948\u6e56\uff0c\u83ca\u5730 \u592e\uff0c\u6885\u5c71 \u60a0\u4f0a\uff0c\u53e4\u5fa1\u5802 \u7d14\uff0c\u4f50\u85e4 \u5cf0\u5609\uff0c\u6b66\u7530 \u907c\uff0cJia Zi, \u7be0\u539f \u4fe1\u96c4\uff0c\u6a0b\u7530 \u6cf0\u6d69\uff0c\u6a0b\u7530 \u4eac\u5b50\uff1a\u304c\u3093\u7d30\u80de\uff0d\u8840\u7ba1\u5185\u76ae\u7d30\u80deCluster\u5f62\u6210\u306b\u3088\u308b\u304c\u3093\u60aa\u6027\u5316\u4fc3\u9032, Tumor endothelial cells promotes metastasis by forming cell clusters with tumor cells, \u53e3\u6f14, \u7b2c31\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2022.7.7<\/span><\/li>\n
        28. Li YU, Nako MAISHI, Erika AKAHORI, Akira HASEBE, Aya MATSUDA, Yoshimasa KITAGAWA, Yasuhiro HIDA, <\/span>Kyoko HIDA<\/span>\uff1b\u53e3\u8154\u7d30\u83cc, Streptococcus mutans\u306f, \u8840\u7ba1\u708e\u75c7\u3092\u8a98\u767a\u3057\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b, The oral bacterium Streptococcus mutans promotes tumor metastasis by inducing vascular inflammation, Poster, \u7b2c31\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2022.7.7<\/span><\/li>\n<\/ol>\n

          2021<\/strong><\/p>\n

            \n
          1. \u7a4d\u7530\u5353\u4e5f, \u6b66\u7530\u907c, \u6fa4 \u6d0b\u6587\u3001\u4f50\u3005\u6728 \u9053\u4ec1\u3001\u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u4f50\u85e4 \u5f70\u5f66, \u9ce5\u7fbd \u664b\u8f14, \u4e0a\u6751 \u5065\u592a\u6717, \u7530\u4e2d\u5b8f\u5178, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u30de\u30a6\u30b9\u611f\u67d3\u30e2\u30c7\u30eb\u3092\u7528\u3044\u305fCOVID-19\u91cd\u75c7\u5316\u306b\u304a\u3051\u308b\u8840\u7ba1\u75c5\u614b\u306e\u89e3\u6790, \u53e3\u6f14, \u7b2c29\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.12.11<\/li>\n
          2. \u7a4d\u7530\u5353\u4e5f, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9178\u5316LDL\u53d7\u5bb9\u4f53LOX-1\u30b7\u30b0\u30ca\u30eb\u3092\u4ecb\u3057\u305f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308b\u597d\u4e2d\u7403\u904a\u8d70\u4fc3\u9032\u3068\u304c\u3093\u8ee2\u79fb\u8a98\u5c0e, \u53e3\u6f14, \u7b2c29\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.12.11<\/li>\n
          3. \u9593\u77f3\u5948\u6e56, \u65b0\u5c71 \u5b97\uff0c\u677e\u7530\u3000\u5f69, \u5927\u5ee3\u6d0b\u4e00, \u4e0a\u7530\u502b\u5f18, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u306e\u5f79\u5272, \u53e3\u6f14, \u7b2c29\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.12.10<\/li>\n
          4. \u7af9\u5ddd\u82f1\u8f1d, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u7a4d\u7530\u5353\u4e5f, Alam MT, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5ddd\u5584\u653f, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u5019\u88dc\u85ac\u306e\u691c\u8a0e, \u53e3\u6f14, \u7b2c29\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.12.10<\/li>\n
          5. \u65b0\u5c71 \u5b97, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69,\u3000\u5927\u5ee3\u6d0b\u4e00, \u4e0a\u7530\u502b\u5f18, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u3068\u81e8\u5e8a\u7684\u56e0\u5b50\u3068\u306e\u95a2\u9023, \u30dd\u30b9\u30bf\u30fc, \u7b2c66\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2021.11.12-14\uff08WEB\u958b\u50ac\uff09<\/li>\n
          6. \u6b66\u7530 \u907c\uff0c\u9593\u77f3 \u5948\u6e56\uff0c\u6a0b\u7530<\/u> \u4eac\u5b50<\/u>\uff1a\u6d17\u53e3\u6db2\u4e2d\u6bba\u83cc\u6210\u5206\u30bb\u30c1\u30eb\u30d4\u30ea\u30b8\u30cb\u30a6\u30e0\u5869\u5316\u7269\u6c34\u548c\u7269\u306eSARS-CoV-2\u306b\u5bfe\u3059\u308b\u52b9\u679c\uff0cThe virucidal effects of cetylpyridinium chloride as antiseptic substances in mouthwash against SARS-CoV-2, Poster, \u7b2c63\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\uff0c10.9-11\uff08WEB\u958b\u50ac\uff09<\/li>\n
          7. \u4f50\u85e4\u5cf0\u5609\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u677e\u7530\u3000\u5f69\uff0c\u4eca\u91ce\u3000\u54f2\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aAngiogenic inhibitor administration prior to immunotherapy improves the therapeutic effects\uff0c\u514d\u75ab\u7642\u6cd5\u306b\u5148\u884c\u3057\u305f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u6295\u4e0e\u306f\u6cbb\u7642\u52b9\u679c\u3092\u6539\u5584\u3059\u308b\uff0c\u53e3\u6f14\uff0c\u7b2c80\u56de\u65e5\u672c\u764c\u5b66\u4f1a\uff0c10.2\uff08\u6a2a\u6d5c\uff0cHybrid\u958b\u50ac\uff09<\/li>\n
          8. Maishi N, Umeyama Y, Kikuchi H, Furumido J, Sato M, Takeda R, Shinohara N, Hida Y, Hida K<\/u>\uff1aPromotion of tumor metastasis by forming tumor cell clusters with tumor endothelial cells, Poster, \u7b2c80\u56de\u65e5\u672c\u764c\u5b66\u4f1a\uff0c10.1\uff08\u6a2a\u6d5c\uff0cHybrid\u958b\u50ac\uff09<\/li>\n
          9. \u7af9\u5ddd\u82f1\u8f1d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530\u3000\u5f69\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aA Novel Angiogenesis Inhibitor Candidate that Targets tumor endothelial marker, Biglycan\uff0cBiglycan\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u5019\u88dc\u85ac\u306e\u691c\u8a0e\uff0e\u53e3\u6f14\uff0c\u7b2c80\u56de\u65e5\u672c\u764c\u5b66\u4f1a\uff0c10.1\uff08\u6a2a\u6d5c\uff0cHybrid\u958b\u50ac\uff09<\/li>\n
          10. \u7a4d\u7530\u5353\u4e5f\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530\u3000\u5f69\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor endothelial cells induce metastasis by neutrophil recruitment into tumor via LOX-1\/Oxidized LDL axis, \u816b\u760d \u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306f\u9178\u5316LDL\u53d7\u5bb9\u4f53LOX-1\u30b7\u30b0\u30ca\u30eb\u3092\u4ecb\u3057\u3066\u597d\u4e2d\u7403\u904a\u8d70\u4fc3\u9032\u3068\u764c\u306e\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b, \u53e3\u6f14\uff0c\u7b2c80\u56de\u65e5\u672c\u764c\u5b66\u4f1a\uff0c10.1\uff08\u6a2a\u6d5c\uff0cHybrid\u958b\u50ac\uff09<\/li>\n
          11. \u7af9\u5ddd\u82f1\u8f1d\uff0c\u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69 ,\u7a4d\u7530\u5353\u4e5f, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5ddd\u5584\u653f, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u5264\u5019\u88dc\u85ac\u306e\u691c\u8a0e, \u53e3\u6f14, \u7b2c54\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2021.9.18\uff08WEB\u958b\u50ac\uff09<\/li>\n
          12. \u6b66\u7530\u3000\u907c\uff0c\u6fa4\u3000\u6d0b\u6587\uff0c\u4f50\u3005\u6728\u9053\u4ec1\uff0c\u5927\u5834\u9756\u5b50\uff0c\u9ce5\u7fbd\u664b\u8f14\uff0c\u4e0a \u5065\u592a\u6717\uff0c\u4f50\u85e4\u3000\u5f70\u5f66\uff0c\u7a4d\u7530\u5353\u4e5f\uff0c\u7530\u4e2d\u5b8f\u5178\uff0c\u4efb\u3000\u5b50\u9a4d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u30bb\u30c1\u30eb\u30d4\u30ea\u30b8\u30cb\u30a6\u30e0\u5869\u5316\u7269\u6c34\u548c\u7269\u306eSARS-CoV-2\u306b\u5bfe\u3059\u308b\u52b9\u679c,\u3000\u53e3\u6f14\uff0c\u7b2c54\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2021.9.18\uff08WEB\u958b\u50ac\uff09<\/li>\n
          13. YU L, Maishi N, Akahori E, Hasebe A, Matsuda A, Annan DA, Li C, Kitagawa Y, Hida K<\/u>\uff1aOral bacteria-induced vascular inflammation as a potent mechanism of tumor metastasis, \u53e3\u6f14, \u7b2c54\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2021.9.18\uff08WEB\u958b\u50ac\uff09<\/li>\n
          14. \u7a4d\u7530\u5353\u4e5f\uff1a\u9178\u5316LDL\u53d7\u5bb9\u4f53LOX-1\u30b7\u30b0\u30ca\u30eb\u3092\u4ecb\u3057\u305f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308b\u597d\u4e2d\u7403\u904a\u8d70\u4fc3\u9032\u3068\u304c\u3093\u8ee2\u79fb\u8a98\u5c0e\uff0c\u7b2c16\u56de\u5148\u7aef\u6b6f\u5b66\u30b9\u30af\u30fc\u30eb\uff0c2021.8.23\uff08WEB\u958b\u50ac\uff09<\/li>\n
          15. \u677e\u7530\u3000\u5f69\uff0c\u5317\u6751\u54f2\u4e5f\uff0c\u6751\u4e95\u77e5\u4f73\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6771\u91ce\u53f2\u88d5\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5c0b\u5e38\u6027\u5929\u75b1\u7621\u3068\u5408\u4f75\u3057\u8a3a\u65ad\u304c\u56f0\u96e3\u3067\u3042\u3063\u305f\u5b54\u9053\u764c\u306e\u4e00\u4f8b\uff0c\u53e3\u6f14\uff0c\u7b2c32\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u3000\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff0c8.12\uff08WEB\u958b\u50ac\uff09<\/li>\n
          16. \u7a4d\u7530\u5353\u4e5f\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9178\u5316LDL\u53d7\u5bb9\u4f53LOX-1\u306e\u816b\u760d\u8840\u7ba1\u306b\u304a\u3051\u308b\u767a\u73fe\u3068\u305d\u306e\u610f\u7fa9\uff0cPoster, \u7b2c30\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\uff0c7.29-30\uff08WEB\u958b\u50ac\uff09<\/li>\n
          17. Li C, Maishi N, Hida Y, Hida K<\/u>: Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy, Poster, \u7b2c30\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\uff0c7.29-30\uff08WEB\u958b\u50ac\uff09<\/li>\n
          18. \u677e\u7530\u3000\u5f69, \u65b0\u5c71\u3000\u5b97, \u9593\u77f3\u5948\u6e56, \u4e0a\u7530\u502b\u5f18, \u6a0b\u7530\u4eac\u5b50<\/u>: \u53e3\u8154\u764c\u306b\u304a\u3051\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u306e\u5f79\u5272\u306e\u691c\u8a0e, \u7b2c110\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2021.4.22-24\uff08WEB\u958b\u50ac\uff09<\/li>\n
          19. \u9593\u77f3 \u5948\u6e56\uff0c\u6885\u5c71 \u60a0\u4f0a\uff0c\u83ca\u5730 \u592e\uff0c\u53e4\u5fa1\u5802 \u7d14\uff0c\u4f50\u85e4 \u5cf0\u5609\uff0c\u6b66\u7530 \u907c\uff0cDorcas A. Annan, \u7be0\u539f \u4fe1\u96c4\uff0c\u6a0b\u7530 \u6cf0\u6d69\uff0c\u6a0b\u7530<\/u> \u4eac\u5b50<\/u>\uff1aCrosstalk of tumor cells and tumor endothelial cells by forming cell clusters promotes tumor metastasis, \u7b2c28\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.3.12\uff08WEB\u958b\u50ac\uff09<\/li>\n
          20. Li C, \u9593\u77f3\u5948\u6e56, Annan DA, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>: Title in English: Inhibition of stromal biglycan normalizes tumor microenvironment and enhances chemotherapeutic efficacy, \u7b2c28\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.3.12\uff08WEB\u958b\u50ac\uff09<\/li>\n
          21. \u65b0\u5c71\u3000\u5b97, \u9593\u77f3\u5948\u6e56, \u677e\u7530\u3000\u5f69, \u6a0b\u7530\u6cf0\u6d69, \u912d\u3000\u6f22\u5fe0, \u4e0a\u7530\u502b\u5f18, \u6a0b\u7530\u4eac\u5b50: Association between high endothelial venules and clinical factors in oral squamous cell carcinoma, \u7b2c28\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.3.12\uff08WEB\u958b\u50ac\uff09<\/li>\n
          22. \u7a4d\u7530\u5353\u4e5f, Annan DA, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>: The role of LOX-1 in tumor endothelial cells on tumor metastasis, \u7b2c28\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.3.12\uff08WEB\u958b\u50ac\uff09<\/li>\n
          23. \u4f50\u85e4\u5cf0\u5609, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u4eca\u91ce\u54f2, \u6a0b\u7530\u4eac\u5b50<\/u>: Vascular normalization window and tumor immunity of mouse lung cancer, \u7b2c28\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.3.12\uff08WEB\u958b\u50ac\uff09<\/li>\n
          24. Yu L, Maishi N, Akahori E, HASEBE A, Annan DA, Li C, Sato M, JIA Z, Kitagawa Y, Hida K*<\/u>: Oral bacteria-induced vascular inflammation as a potent mechanism of tumor metastasis, \u7b2c28\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2021.3.12\uff08WEB\u958b\u50ac\uff09<\/li>\n<\/ol>\n

            2020<\/strong><\/p>\n

              \n
            1. <\/li>\n
            2. \u7a4d\u7530\u5353\u4e5f, \u68ee\u672c\u771f\u5f18, \u9593\u77f3\u5948\u6e56, \u5409\u5ca1\u7950\u4eae, \u6a0b\u7530\u6cf0\u6d69, \u677e\u7530\u3000\u5f69, \u6771\u91ce\u53f2\u88d5, \u843d\u8c37\u5b5d\u5e83, \u6a0b\u7530\u4eac\u5b50<\/u>: \u304c\u3093\u7d30\u80de\u30a8\u30af\u30bd\u30bd\u30fc\u30e0microRNA-1246\u306f\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3044\u3066\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u5fdc\u7b54\u3092\u6d3b\u6027\u5316\u3059\u308b, \u53e3\u982d, \u7b2c7\u56de\u65e5\u672c\u7d30\u80de\u5916\u5c0f\u80de\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2020.10.27\uff08WEB\u958b\u50ac\uff09<\/li>\n
            3. \u7a4d\u7530\u5353\u4e5f, \u68ee\u672c\u771f\u5f18, \u9593\u77f3\u5948\u6e56, \u5409\u5ca1\u7950\u4eae, \u6a0b\u7530\u6cf0\u6d69, \u677e\u7530\u3000\u5f69, \u6771\u91ce\u53f2\u88d5, \u843d\u8c37\u5b5d\u5e83, \u6a0b\u7530\u4eac\u5b50<\/u>: \u304c\u3093\u7d30\u80de\u30a8\u30af\u30bd\u30bd\u30fc\u30e0microRNA-1246\u306f\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3044\u3066\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u5fdc\u7b54\u3092\u6d3b\u6027\u5316\u3059\u308b, \u30dd\u30b9\u30bf\u30fc, \u7b2c7\u56de\u65e5\u672c\u7d30\u80de\u5916\u5c0f\u80de\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2020.10.27\uff08WEB\u958b\u50ac\uff09<\/li>\n
            4. \u67cf\u539f\u307f\u3086\u304d, \u6817\u6797\u548c\u4ee3, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u4eac\u5b50<\/span>, \u912d\u3000\u6f22\u5fe0: \u982c\u7c98\u819c\u306b\u751f\u3058\u305f\u56a2\u80de\u817a\u816b\u306e 1 \u4f8b\uff08\u53e3\u5916\uff09, \u7b2c46\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u5317\u65e5\u672c\u652f\u90e8\u5b66\u8853\u96c6\u4f1a, 2020.11.2-3(WEB\u958b\u50ac)<\/li>\n
            5. Annan DA, Maishi N, Soga T, Dawood RIH, Li C, Kikuchi H, Hojo T, Morimoto M, Kitamura T, Alam MT, Minowa K, Shinohara N, Nam JM, Hida Y and Hida K<\/u>: Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment, \u30dd\u30b9\u30bf\u30fc, \u7b2c6\u56de\u5317\u6d77\u9053\u5927\u5b66\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u201c\u82e5\u624b\u7814\u7a76\u8005\u306b\u3088\u308b\u751f\u547d\u3068\u7269\u8cea\u306e\u878d\u5408\u3092\u76ee\u6307\u3057\u3066\uff01\u201d, 2020.10.19\uff08WEB\u958b\u50ac\uff09<\/li>\n
            6. Li C, Maishi N, Annan DA, Young MF, Hida Y, Hida K<\/u>: Inhibition of biglycan normalizes tumor blood vessels and potentiates tumor immune responses, \u30dd\u30b9\u30bf\u30fc, \u7b2c6\u56de\u5317\u6d77\u9053\u5927\u5b66\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u201c\u82e5\u624b\u7814\u7a76\u8005\u306b\u3088\u308b\u751f\u547d\u3068\u7269\u8cea\u306e\u878d\u5408\u3092\u76ee\u6307\u3057\u3066\uff01\u201d, 2020.10.19\uff08WEB\u958b\u50ac\uff09<\/li>\n
            7. \u7a4d\u7530\u5353\u4e5f, Annan DA, \u9593\u77f3\u5948\u6e56, \u677e\u7530 \u5f69, \u6a0b\u7530\u6cf0\u6d69, \u6771\u91ce\u53f2\u88d5, \u6a0b\u7530\u4eac\u5b50<\/u>: \u9178\u5316LDL \u53d7\u5bb9\u4f53LOX-1 \u306e\u816b\u760d\u8840\u7ba1\u306b\u304a\u3051\u308b\u6a5f\u80fd\u89e3\u6790, \u30dd\u30b9\u30bf\u30fc, \u7b2c6\u56de\u5317\u6d77\u9053\u5927\u5b66\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u201c\u82e5\u624b\u7814\u7a76\u8005\u306b\u3088\u308b\u751f\u547d\u3068\u7269\u8cea\u306e\u878d\u5408\u3092\u76ee\u6307\u3057\u3066\uff01\u201d, 2020.10.19\uff08WEB\u958b\u50ac\uff09<\/li>\n
            8. \u7530\u4e2d\u5b8f\u5178, \u9593\u77f3\u5948\u6e56, \u68ee\u672c\u6d69\u53f2, \u4e2d\u6751\u3000\u900f, \u6a0b\u7530\u6cf0\u6d69, \u5e73\u91ce\u3000\u8061, \u6a0b\u7530\u4eac\u5b50<\/u>: \u81b5\u81d3\u306e\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bbiglycan\u306e\u767a\u73fe\u3068\u81e8\u5e8a\u75c5\u7406\u5b66\u7684\u56e0\u5b50\u306e\u691c\u8a0e, \u7b2c122\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a, 2020.10.17\uff08\u672d\u5e4c\uff09<\/li>\n
            9. Li C, Maishi N, Annan DA, Hida Y, Hida K<\/u>: Inhibition of biglycan normalizes tumor blood vessels and potentiates tumor immune responses, \u7b2c122\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a, 2020.10.17\uff08\u672d\u5e4c\uff09<\/li>\n
            10. \u7a4d\u7530\u5353\u4e5f\uff0cAnnan DA\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530 \u5f69\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6771\u91ce\u53f2\u88d5\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: \u9178\u5316LDL\u53d7\u5bb9\u4f53LOX\u20101\u306e\u816b\u760d\u8840\u7ba1\u306b\u304a\u3051\u308b\u767a\u73fe\u3068\u305d\u306e\u610f\u7fa9, \u7b2c53\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2020.10.10\uff08WEB\u958b\u50ac\uff09<\/li>\n
            11. \u53e4\u5fa1\u5802 \u7d14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530 \u5f69\uff0c\u6771\u91ce\u53f2\u88d5\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: \u60aa\u6027\u5ea6\u306e\u7570\u306a\u308b\u524d\u7acb\u817a\u304c\u3093\u306b\u304a\u3051\u308b\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306e\u9055\u3044\u7b2c53\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2020.10.10\uff08WEB\u958b\u50ac\uff09<\/li>\n
            12. \u7530\u4e2d\u5b8f\u5178\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u68ee\u672c\u6d69\u53f2\uff0c\u4e2d\u6751 \u900f\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5e73\u91ce \u8061\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: \u81b5\u764c\u306e\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bbiglycan\u306e\u767a\u73fe\u3068\u81e8\u5e8a\u75c5\u7406\u5b66\u7684\u56e0\u5b50\u306e\u691c\u8a0e, \u7b2c53\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2020.10.10\uff08WEB\u958b\u50ac\uff09<\/li>\n
            13. \u65b0\u5c71 \u5b97\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u677e\u7530 \u5f69\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u912d \u6f22\u5fe0\uff0c\u4e0a\u7530\u502b\u5f18\uff0c\u6a0b\u7530<\/u> \u4eac\u5b50<\/u>: \u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u3068\u81e8\u5e8a\u7684\u56e0\u5b50\u3068\u306e\u95a2\u9023, \u7b2c53\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2020.10.10\uff08WEB\u958b\u50ac\uff09<\/li>\n
            14. \u7be0\u539f\u65e9\u7d00\uff0c\u677e\u7530 \u5f69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u6751\u54f2\u4e5f\uff0c\u4e0a\u7530\u502b\u5f18\uff0c\u5927\u5ee3\u6d0b\u4e00\uff0c\u912d \u6f22\u5fe0\uff0c\u6771\u91ce\u53f2\u88d5\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: \u30a8\u30ca\u30e1\u30eb\u4e0a\u76ae\u816b\u306ebudding\u5f62\u6210\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u691c\u8a0e\u7b2c53\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a, 2020.10.10\uff08WEB\u958b\u50ac\uff09<\/li>\n
            15. Li C, Maishi N, Annan DA, Hida Y, Hida K<\/span>: Stroma Biglycan deficiency normalizes tumor blood vessels and potentiates tumor immune responses, Oral, The 79th Annual Meeting og the Japanese Cancer Association, 2020.10.1-3, Hiroshima, Web Conference<\/li>\n
            16. Annan DA, Maishi N, Soga T, Hojo T, Hida Y, Hida K<\/span>: Glutamine metabolism facilitates tumor endothelial cell proliferation via redox homeostasis, Oral, The 79th Annual Meeting og the Japanese Cancer Association, 2020.10.1-3, Hiroshima, Web Conference<\/li>\n
            17. \u4f50\u85e4\u5cf0\u5609, Li C, \u9593\u77f3\u5948\u6e56, Annan DA, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/span>: \u80ba\u764c\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b Biglycan \u306e\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u53ca\u307c\u3059\u5f71\u97ff, \u53e3\u6f14, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2020.10.1-3\uff08\u5e83\u5cf6, WEB\u958b\u50ac\uff09<\/li>\n
            18. \u7a4d\u7530\u5353\u4e5f, Annan DA, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/span>: \u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u304c\u767a\u73fe\u3059\u308b LOX-1 \u306e\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u5f79\u5272, \u53e3\u6f14, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2020.10.1-3\uff08\u5e83\u5cf6, WEB\u958b\u50ac\uff09<\/li>\n
            19. \u9593\u77f3\u5948\u6e56, \u6afb\u4e95 \u904a, \u7560\u5c71\u6d69\u4eba, Li C, Alam MT, \u83ca\u5730 \u592e, \u68ee\u672c\u6d69\u53f2, \u68ee\u672c\u771f\u5f18, \u6a0b\u7530\u6cf0\u6d69, \u539f\u5cf6\u79c0\u5409, \u6a0b\u7530\u4eac\u5b50<\/span>: \u30ea\u30dd\u30bd\u30fc\u30e0 siRNA \u30c7\u30ea\u30d0\u30ea\u30fc\u30b7\u30b9\u30c6\u30e0\u3092\u7528\u3044\u305f\u816b\u760d\u8840\u7ba1 biglycan \u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5, \u53e3\u6f14, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2020.10.1-3\uff08\u5e83\u5cf6, WEB\u958b\u50ac\uff09<\/li>\n
            20. \u53e4\u5fa1\u5802 \u7d14, \u9593\u77f3\u5948\u6e56, Annan DA, \u7be0\u539f\u4fe1\u96c4, \u6a0b\u7530\u4eac\u5b50<\/span>: \u60aa\u6027\u5ea6\u306e\u7570\u306a\u308b\u524d\u7acb\u817a\u304c\u3093\u306e\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306e\u9055\u3044, \u30dd\u30b9\u30bf\u30fc, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2020.10.1-3\uff08\u5e83\u5cf6, WEB\u958b\u50ac\uff09<\/li>\n
            21. \u7530\u4e2d\u5b8f\u5178, \u9593\u77f3\u5948\u6e56, \u68ee\u672c\u6d69\u53f2, Annan DA, \u4e2d\u6751 \u900f, \u6a0b\u7530\u6cf0\u6d69, \u5e73\u91ce \u8061, \u6a0b\u7530\u4eac\u5b50<\/span>: \u81b5\u764c\u306e\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308b biglycan \u767a\u73fe\u306e\u81e8\u5e8a\u7684\u610f\u7fa9\u306e\u691c\u8a0e, \u30dd\u30b9\u30bf\u30fc, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2020.10.1-3\uff08\u5e83\u5cf6, WEB\u958b\u50ac\uff09<\/li>\n
            22. \u65b0\u5c71 \u5b97, \u9593\u77f3\u5948\u6e56, \u677e\u7530 \u5f69, \u6a0b\u7530\u4eac\u5b50<\/span>: \u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u3068\u81e8\u5e8a\u7684\u56e0\u5b50\u3068\u306e\u95a2\u9023, \u30dd\u30b9\u30bf\u30fc, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2020.10.1-3\uff08\u5e83\u5cf6, WEB\u958b\u50ac\uff09<\/li>\n
            23. \u677e\u7530\u3000\u5f69\uff0c\u5317\u6751\u54f2\u4e5f\uff0c\u5742\u7530\u5065\u4e00\u90ce\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6771\u91ce\u53f2\u88d5\uff0c\u6a0b\u7530\u4eac\u5b50<\/span>: \u6241\u5e73\u4e0a\u76ae\u764c\u3068\u306e\u9451\u5225\u306b\u82e6\u616e\u3057\u305f\u57fa\u5e95\u7d30\u80de\u764c\u306e\u4e00\u4f8b\uff0c\u7b2c31\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff0c9.16-10.6 \uff08WEB\u958b\u50ac\uff09<\/li>\n
            24. \u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u4eac\u5b50<\/span>: \u6297\u764c\u5264\u6cbb\u7642\u304c\u3082\u305f\u3089\u3059\u816b\u760d\u8840\u7ba1ABCB1\u767a\u73fe\u4ea2\u9032\u3068\u305d\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u89e3\u660e\uff0c\u7b2c31\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff0c9.16-10.6 \uff08WEB\u958b\u50ac\uff09<\/li>\n
            25. \u677e\u7530\u3000\u5f69\uff0c\u65b0\u5c71\u3000\u5b97, \u9593\u77f3\u5948\u6e56, \u6771\u91ce\u53f2\u88d5, \u6a0b\u7530\u4eac\u5b50<\/span>: \u53e3\u8154\u304c\u3093\u306b\u5b58\u5728\u3059\u308b\u9ad8\u5185\u76ae\u7d30\u9759\u8108\u306e\u81e8\u5e8a\u7684\u610f\u7fa9\u306e\u691c\u8a0e\uff0c\u7b2c62\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\uff0c9.11-10.9\uff08WEB\u958b\u50ac\uff09<\/li>\n
            26. \u677e\u7530\u3000\u5f69\uff0c\u52a0\u85e4\u6cf0\u53f2\uff0c\u5317\u6751\u54f2\u4e5f\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u4eac\u5b50<\/span>\uff0c\u6771\u91ce\u53f2\u88d5: \u816b\u760d\u6eb6\u89e3\u30a2\u30c7\u30ce\u30a6\u30a4\u30eb\u30b9\u306e\u52b9\u679c\u5897\u5f37\u306e\u305f\u3081\u306e\u8a66\u307f\uff0c\u7b2c109\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c7.1-31\uff08WEB\u958b\u50ac\uff09<\/li>\n
            27. \u9593\u77f3\u5948\u6e56\uff0c\u8d64\u5800\u6c38\u502b\u9999\uff0c\u6a0b\u7530\u4eac\u5b50<\/span>: \u6297\u764c\u5264\u6cbb\u7642\u304c\u3082\u305f\u3089\u3059\u816b\u760d\u8840\u7ba1ABCB1\u767a\u73fe\u4ea2\u9032\u3068\u305d\u306e\u6a5f\u5e8f\uff0c\u7b2c74\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c4.15-5.15\uff08WEB\u958b\u50ac\uff09<\/li>\n
            28. \u7a4d\u7530\u5353\u4e5f, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9178\u5316LDL\u53d7\u5bb9\u4f53LOX-1\u306e\u816b\u760d\u75c5\u614b\u306b\u304a\u3051\u308b\u767a\u8a00\u3068\u75c5\u614b\u751f\u7406\u5b66\u7684\u610f\u7fa9\u306e\u691c\u8a0e, \u7d30\u80de\u793e\u4f1a\u30c0\u30a4\u30d0\u30fc\u30b7\u30c6\u30a3\u30fc\u306e\u7d71\u5408\u7684\u89e3\u660e\u3068\u5236\u5fa1 \u7b2c3\u56de\u82e5\u624b\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7, 2020.2.12-13\uff08\u71b1\u6d77\uff09<\/li>\n
            29. \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u306e\u8ee2\u79fb\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f79\u5272\u89e3\u660e, \u7b2c\uff11\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u82e5\u624b\u306e\u4f1a, 2020.2.2.12\uff08\u71b1\u6d77\uff09<\/li>\n
            30. \u83ca\u5730\u3000\u592e, \u9593\u77f3\u5948\u6e56, Dorcas A.Annan, Mohammad Towfik Alam, Randa Ibrahim Hassan Dawood, \u68ee\u672c\u771f\u5f18, \u677e\u672c\u9686\u5150, \u5927\u6fa4\u5d07\u5b8f, \u5b89\u90e8\u5d07\u91cd, \u6a0b\u7530\u6cf0\u6d69, \u539f\u6797\u3000\u900f, \u677e\u91ce\u5409\u5f18, \u7be0\u539f\u4fe1\u96c4, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u6297\u764c\u5264\u6cbb\u7642\u5f8c\u306e\u816b\u760d\u8840\u7ba1ABCB\uff11\u767a\u73fe\u4ea2\u9032\u3068\u85ac\u5264\u8010\u6027, \u7b2c\uff11\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u82e5\u624b\u306e\u4f1a, 2020.2.2.12\uff08\u71b1\u6d77\uff09<\/li>\n
            31. \u9593\u77f3\u5948\u6e56, \u83ca\u5730\u3000\u592e, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7d30\u80de\u793e\u4f1a\u30c0\u30a4\u30d0\u30fc\u30b7\u30c6\u30a3\u30fc\u306e\u7d71\u5408\u7684\u89e3\u660e\u3068\u5236\u5fa1\u3000\u7b2c5\u56de\u516c\u958b\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u591a\u9762\u76841\u7d30\u80de\u89e3\u6790\u6280\u8853\u304c\u89e3\u304d\u660e\u304b\u3059\u7d30\u80de\u793e\u4f1a\u30c0\u30a4\u30d0\u30fc\u30b7\u30c6\u30a3\u30fc\u300d, \u201c\u6297\u764c\u5264\u6cbb\u7642\u304c\u3082\u305f\u3089\u3059\u816b\u760d\u8840\u7ba1ABCB1\u767a\u73fe\u4ea2\u9032\u3068\u305d\u306e\u6a5f\u5e8f\u201d, 2020.1.29\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n

              2019<\/strong><\/p>\n

                \n
              1. \u7a4d\u7530\u5353\u4e5f, Li Cong, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u677e\u7530\u5f69, \u6771\u91ce\u53f2\u88d5, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7d30\u80de\u5916\u30de\u30c8\u30ea\u30c3\u30af\u30b9Byglycan\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u65b0\u751f\u4ea2\u9032\u306a\u3089\u3073\u306b\u8840\u7ba1\u672a\u6210\u719f\u6027\u304c\u3082\u305f\u3089\u3059\u8ee2\u79fb\u4fc3\u9032, \u7b2c27\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2019.12.15\uff08\u795e\u6238\uff09<\/li>\n
              2. Li Cong, Nako Maishi, Dorcas A. Annan, Marian F. Young, Yasuhiro Hida, Kyoko Hida\uff1aBiglycan promotes tumor angiogenesis, desmoplasia and potentiates tumor immune responses, \u7b2c5\u56de\u5317\u6d77\u9053\u5927\u5b66\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0, 2019.11.5\uff08\u672d\u5e4c\uff09<\/li>\n
              3. \u7a4d\u7530\u5353\u4e5f, \u68ee\u672c\u771f\u5f18, \u9593\u77f3\u5948\u6e56, \u5409\u5ca1\u7950\u4eae, \u6a0b\u7530\u6cf0\u6d69, \u5c0f\u5742\u5c55\u6176, \u677e\u7530\u5f69, \u6771\u91ce\u53f2\u88d5, \u843d\u8c37\u5b5d\u5e83, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u7d30\u80de\u30a8\u30af\u30bd\u30bd\u30fc\u30e0microRNA-1246\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u3068\u8ee2\u79fb\u4fc3\u9032, \u7b2c6\u56de\u65e5\u672c\u7d30\u80de\u5916\u5c0f\u80de\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2019.10.25\uff08\u6771\u4eac\uff09<\/li>\n
              4. \u7be0\u539f\u65e9\u7d00, \u5317\u6751 \u54f2\u4e5f, \u677e\u7530 \u5f69, \u9593\u77f3 \u5948\u6e56, \u6771\u91ce \u53f2\u88d5, \u5927\u5ee3 \u6d0b\u4e00, \u6a0b\u7530<\/u> \u4eac\u5b50<\/u>, \u912d \u6f22\u5fe0\uff1a\u30a8\u30ca\u30e1\u30eb\u4e0a\u76ae\u816b\u306ebudding\u306b\u304a\u3051\u308b\u6d78\u6f64\u5897\u6b96\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u6790, \u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a10.25\uff08\u672d\u5e4c\uff09<\/li>\n
              5. \u683c\u53e3\u6e09, \u68ee\u672c\u771f\u5f18, \u7be0\u539f\u65e9\u7d00, \u9593\u77f3\u5948\u6e56, \u5317\u6751\u54f2\u4e5f, \u6a0b\u7530\u4eac\u5b50<\/u>, \u912d \ufa47\u5fe0\uff1aSuramin\u306fcell cycle\u306b\u95a2\u9023\u3059\u308bmRNA\u306e\u767a\u73fe\u3092\u4f4e\u4e0b\u3055\u305b, \u820c\u764c\u7d30\u80de\u306e\u5897\u6b96\u3092\u6291\u5236\u3059\u308b, \u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a10.25\uff08\u672d\u5e4c\uff09<\/li>\n
              6. Li Cong, Maishi N., Dorcas A. Annan, Hida Y., Hida K.\uff1aStromal biglycan promotes tumor angiogenesis and potentiates tumor immune responses, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2019.9.27\uff08\u4eac\u90fd\uff09<\/li>\n
              7. Maishi N., Dorcas A. Annan, Soga T., Dawood Randa, Li Cong, Kikuchi H., Hojo T., Morimoto M., Kitamura T., Mohammad Towfik Alam, Shinohara N., Hida Y., Hida K<\/u>.\uff1aCarbonic anhydrase 2 (CA\u2161) is essential for tumor endothelial cell proliferation, \u7b2c79\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2019.9.27\uff08\u4eac\u90fd\uff09<\/li>\n
              8. Annan Dorcas A., Maishi N., Soga T., Dawood Randa, Li Cong, Kikuchi H., Hojo T., Morimoto M., Kitamura T., Mohammad Towfik Alam, Minowa K., Shinohara N., Hida Y., Hida K.\uff1aCarbonic anhydrase 2\uff08CAII\uff09is essential for tumor endothelial cell proliferation, \u7b2c108\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c5.11\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n

                2018<\/h4>\n
                  \n
                1. \u68ee\u672c\u771f\u5f18\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u30a8\u30af\u30bd\u30bd\u30fc\u30e0 \u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u306b\u3088\u3063\u3066\u304c\u3093\u306e\u8ee2\u79fb\u304c\u4fc3\u9032\u3055\u308c\u308b\uff0c\u7b2c26\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c12.7\uff08\u6771\u4eac\uff09<\/li>\n
                2. Li Cong, \u9593\u77f3\u5948\u6e56\uff0cYoung Marian F, \u68ee\u672c\u6d69\u53f2, \u68ee\u672c\u771f\u5f18\uff0cAnnan Dorcas A., \u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aThe involvement of stromal biglycan in tumor angiogenesis and metastasis, \u7b2c51\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2018.10.13\uff08\u672d\u5e4c\uff09<\/li>\n
                3. Annan Dorcas A., \u9593\u77f3\u5948\u6e56\uff0c\u66fd\u6211\u670b\u7fa9\uff0c\u7be0\u539f\u4fe1\u96c4\uff0cDawood Randa, Li Cong, \u83ca\u5730\u3000\u592e\uff0c\u5317\u689d\u656c\u4e4b\uff0c\u68ee\u672c\u771f\u5f18\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCarbonic anhydrase 2 (CA\u2161) is essential for tumor endothelial cell proliferation, \u7b2c51\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2018.10.13\uff08\u672d\u5e4c\uff09<\/li>\n
                4. \u68ee\u672c\u771f\u5f18\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5317\u5ddd\u5584\u653f,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0 miRNA \u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u3068\u8ee2\u79fb\u4fc3\u9032\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e\uff0c\u7b2c51\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2018.10.13\uff08\u672d\u5e4c\uff09<\/li>\n
                5. \u68ee\u672c\u771f\u5f18\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0 miRNA \u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u306b\u3088\u308b\u8ee2\u79fb\u4fc3\u9032\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e\uff0c\u7b2c77\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2018.9.28\uff08\u5927\u962a\uff09<\/li>\n
                6. \u83ca\u5730\u3000\u592e\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u571f\u5c4b\u90a6\u5f66\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u6797\u3000\u900f\uff0c\u677e\u91ce\u5409\u5f18\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u6297\u764c\u5264\u6cbb\u7642\u5f8c\u306e\u816b\u760d\u8840\u7ba1ABCB1\u767a\u73fe\u4ea2\u9032\uff0c\u7b2c77\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2018.9.28\uff08\u5927\u962a\uff09<\/li>\n
                7. \u68ee\u672c\u771f\u5f18\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0 miRNA \u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u3068\u8ee2\u79fb\u4fc3\u9032\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e\uff0c\u7b2c60\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\uff0c2018.9.5\uff08\u798f\u5ca1\uff09<\/li>\n
                8. \u68ee\u672c\u771f\u5f18, \u9593\u77f3\u5948\u6e56, \u5317\u5ddd\u5584\u653f,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0miRNA\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u3068\u8ee2\u79fb\u4fc3\u9032\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e\uff0c\u7b2c27\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\uff0c2018.7.20\uff08\u6a2a\u6d5c\uff09<\/li>\n
                9. Dorcas A. Annan1, Maishi N., Soga T., Randa Dawood, Hida Y. and Hida K.\uff1aGlutamine Metabolism in Tumor Endothelial Cells, \u7b2c107\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2018.6.23\uff08\u672d\u5e4c\uff09<\/li>\n
                10. Maishi N., Kikuchi H., Abe T., Maruyama S., Harabayashi T., Ameda K., Matsuno Y., Hida Y., Shinohara N.,\u00a0Hida K.<\/u>\uff1aMDR1\/ABCB1 upregulation in tumor blood vessels by chemotherapy-induced IL-8\uff0c\u7b2c107\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2018.6.22\uff08\u672d\u5e4c\uff09<\/li>\n
                11. \u68ee\u672c\u771f\u5f18, \u9593\u77f3\u5948\u6e56, \u83ca\u5730\u3000\u592e, \u5317\u5ddd\u5584\u653f,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0miRNA\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u3068\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c107\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2018.6.22\uff08\u672d\u5e4c\uff09<\/li>\n
                12. \u68ee\u672c\u6d69\u53f2, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u897f\u539f\u5e83\u53f2, \u7551\u4e2d\u3000\u8c4a, \u677e\u91ce\u5409\u5b8f, \u4e2d\u6751\u3000\u900f, \u5e73\u91ce\u3000\u8061,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u80ba\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u30de\u30fc\u30ab\u30fcbiglycan\u306e\u767a\u73fe\u89e3\u6790\uff0c\u7b2c107\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2018.6.21\uff08\u672d\u5e4c\uff09<\/li>\n
                13. \u68ee\u672c\u771f\u5f18, \u9593\u77f3\u5948\u6e56, \u5317\u5ddd\u5584\u653f,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0miRNA\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u3068\u8ee2\u79fb\u4fc3\u9032\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e\uff0c\u7b2c72\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2018.5.13\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                14. Dorcas A. Annan, Maishi N., Soga T., Randa Dawood, Hida Y. and Hida K.\uff1aGlutamine Metabolism in Tumor Endothelial Cells\uff0c\u7b2c\uff13\u56de\u5317\u5927\u30fb\u90e8\u5c40\u6a2a\u65ad\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u7814\u7a76\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u4fc3\u9032\u30d7\u30ed\u30b0\u30e9\u30e0\uff5eYoung Researchers in Cutting-edge Life Science\uff5e\uff0c2018.1.26\uff08\u672d\u5e4c\uff09<\/li>\n<\/ol>\n

                  2017<\/h4>\n
                    \n
                  1. Dorcas A. Annan, Maishi N., Soga T., Randa Dawood, Hida Y. and\u00a0Hida K<\/u>.\uff1aGlutamine Metabolism in Tumor Endothelial Cells\uff0c\u7b2c8\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2017.12.20\uff08\u672d\u5e4c\uff09<\/li>\n
                  2. \u4f50\u85e4\u771f\u73e0\u7f8e\uff0c\u83ca\u5730\u3000\u592e\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9ad8\u5009\u4f38\u5e78\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6297\u764c\u5264\u6cbb\u7642\u304c\u816b\u760d\u8840\u7ba1\u3068\u304c\u3093\u5e79\u7d30\u80de\u306b\u53ca\u307c\u3059\u5f71\u97ff\uff0c\u7b2c8\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2017.12.20\uff08\u672d\u5e4c\uff09<\/li>\n
                  3. \u68ee\u672c\u771f\u5f18\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u83ca\u5730\u3000\u592e\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0miRNA\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u5f62\u8cea\u5909\u5316\u3068\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c8\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2017.12.20\uff08\u672d\u5e4c\uff09<\/li>\n
                  4. \u68ee\u672c\u6d69\u53f2\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u897f\u539f\u5e83\u53f2\uff0c\u7551\u4e2d\u3000\u8c4a\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u4e2d\u6751\u3000\u900f\uff0c\u5e73\u91ce\u3000\u8061\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u80ba\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u30de\u30fc\u30ab\u30fcbiglyca\u306e\u767a\u73fe\u89e3\u6790\uff0c\u7b2c8\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2017.12.20\uff08\u672d\u5e4c\uff09<\/li>\n
                  5. \u9593\u77f3\u5948\u6e56\uff0c\u83ca\u5730\u3000\u592e\uff0cMohammad Towfik Alam\uff0cRanda Ibrahim Hassan Dawood\uff0c\u6b66\u7530\u3000\u907c\uff0c\u77f3\u585a\u5553\u592a\uff0c\u677e\u672c\u9686\u5150\uff0c\u79cb\u91ce\u6587\u81e3\uff0c\u571f\u5c4b\u90a6\u5f66\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5bae\u5cf6\u3000\u76f4\u4eba\uff0c\u4e38\u5c71\u3000\u899a\uff0c\u539f\u6797\u3000\u900f\uff0c\u5c71\u57ce\u52dd\u91cd\uff0c\u98f4\u7530\u3000\u8981\uff0c\u67cf\u6728\u3000\u660e\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u6297\u304c\u3093\u5264\u6cbb\u7642\u304c\u3082\u305f\u3089\u3059\u816b\u760d\u8840\u7ba1\u306e\u8010\u6027\u7372\u5f97\uff0c\u7b2c8\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2017.12.20\uff08\u672d\u5e4c\uff09<\/li>\n
                  6. \u68ee\u672c\u6d69\u53f2\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u897f\u539f\u5e83\u53f2\uff0c\u7551\u4e2d\u3000\u8c4a\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u5e73\u91ce\u3000\u8061\uff0c\u6a0b\u7530\u4eac\u5b50\uff1a\u80ba\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u30de\u30fc\u30ab\u30fcbiglycan\u306e\u767a\u73fe\u89e3\u6790, \u7b2c116\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2017.10.21\uff08\u672d\u5e4c\uff09<\/li>\n
                  7. Dorcas A.Annan,\u3000\u9593\u77f3\u5948\u6e56\uff0c\u66fd\u6211\u670b\u7fa9\uff0cDawood Randa, \u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aGlutamine Metabolism in Tumor Endothelial Cells, \u7b2c116\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2017.10.21\uff08\u672d\u5e4c\uff09<\/li>\n
                  8. Dorcas A.Annan, Maishi N., Soga T., Randa Dawood, Hida Y.,\u00a0Hida K.<\/u>\uff1aGlutamine Metabolism in Tumor Endothelial Cells, \u7b2c76\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2017.9.30\uff08\u6a2a\u6d5c\uff09<\/li>\n
                  9. \u9593\u77f3\u5948\u6e56\uff0c\u83ca\u5730\u3000\u592e\uff0c\u68ee\u672c\u6d69\u53f2\uff0c\u571f\u5c4b\u90a6\u5f66\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u6797\u3000\u900f\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c76\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2017.9.29\uff08\u6a2a\u6d5c\uff09<\/li>\n
                  10. \u68ee\u672c\u6d69\u53f2\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u897f\u539f\u5e83\u53f2\uff0c\u7551\u4e2d\u3000\u8c4a\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u4e2d\u6751\u3000\u900f\uff0c\u5e73\u91ce\u3000\u8061\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u80ba\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u30de\u30fc\u30ab\u30fcbiglycan\u306e\u767a\u73fe\u89e3\u6790\uff0c\u7b2c76\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2017.9.29\uff08\u6a2a\u6d5c\uff09<\/li>\n
                  11. \u68ee\u672c\u771f\u5f18, \u9593\u77f3\u5948\u6e56,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u7531\u6765\u30a8\u30af\u30bd\u30bd\u30fc\u30e0miRNA\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u85ac\u5264\u8010\u6027\u8a98\u5c0e, \u7b2c59\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2017.9.16\uff08\u677e\u672c\uff09<\/li>\n
                  12. \u6b66\u7530\u3000\u907c\uff0c\u68ee\u672c\u771f\u5f18\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6297\u764c\u5264\u6cbb\u7642\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u8010\u6027\u7372\u5f97\u6a5f\u69cb, \u7b2c59\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a, 2017.9.16\uff08\u677e\u672c\uff09<\/li>\n
                  13. \u9593\u77f3\u5948\u6e56, \u9ce5\u5c45\u3061\u3055\u307b, \u5ddd\u672c\u6cf0\u8f14, \u68ee\u672c\u771f\u5f18, \u79cb\u5c71\u5ee3\u8f14, \u5409\u5ca1\u7950\u4eae, Alam Mohammad Towfik, \u5357\u3000\u656c, \u843d\u8c37\u5b5d\u5e83, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760dmiR\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308b\u85ac\u5264\u8010\u6027\u8a98\u5c0e, \u7b2c26\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2017.7.28\uff08\u5927\u962a\uff09<\/li>\n
                  14. \u83ca\u5730\u3000\u592e, \u9593\u77f3\u5948\u6e56, \u79cb\u5c71\u5ee3\u8f14, \u68ee\u672c\u771f\u5f18, \u571f\u5c4b\u90a6\u5f66, \u4e38\u5c71\u3000\u899a, \u5b89\u90e8\u5d07\u91cd, \u6a0b\u7530\u3000\u6cf0\u6d69, \u539f\u6797\u3000\u900f, \u98f4\u7530\u3000\u8981, \u677e\u672c\u9686\u5150, \u67cf\u6728\u3000\u660e, \u677e\u91ce\u5409\u5b8f, \u7be0\u539f\u4fe1\u96c4,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u6297\u764c\u5264\u6cbb\u7642\u5f8c\u306e\u816b\u760d\u8840\u7ba1ABCB1\u767a\u73fe\u4ea2\u9032\uff0c\u7b2c26\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2017.7.28(\u5927\u962a\uff09<\/li>\n
                  15. \u68ee\u672c\u6d69\u53f2, \u9593\u77f3\u5948\u6e56, \u6a0b\u7530\u6cf0\u6d69, \u897f\u539f\u5e83\u53f2, \u7551\u4e2d\u3000\u8c4a, \u677e\u91ce\u5409\u5b8f, \u4e2d\u6751\u3000\u900f, \u5e73\u91ce\u3000\u8061,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u80ba\u764c\u75c7\u4f8b\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u30de\u30fc\u30ab\u30fcbiglycan\u306e\u767a\u73fe\u89e3\u6790, \u7b2c26\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2017.7.28\uff08\u5927\u962a\uff09<\/li>\n
                  16. Randa Ibrahim Dawood, Yanagiya M., Maishi N., Hida Y., Torii C., Kikuchi H., Ohga N., Tei K., Kitakura T., Shindoh M.,\u00a0Hida K<\/u>.\uff1aCorrelation between endothelial CXCR7 expression and clinic pathological factors in oral squamous cell carcinoma (OSCC)\uff0c\u7b2c5\u56de\u304c\u3093\u3068\u4ee3\u8b1d\u7814\u7a76\u4f1a in \u672d\u5e4c\uff0c2017.7.14\uff08\u672d\u5e4c\uff09<\/li>\n
                  17. \u68ee\u672c\u771f\u5f18\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5409\u5ca1\u7950\u4eae\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u30a8\u30af\u30bd\u30bd\u30fc\u30e0miR\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u85ac\u5264\u8010\u6027\u8a98\u5c0e\uff0c\u7b2c5\u56de\u304c\u3093\u3068\u4ee3\u8b1d\u7814\u7a76\u4f1a in \u672d\u5e4c\uff0c2017.7.14\uff08\u672d\u5e4c\uff09<\/li>\n
                  18. \u68ee\u672c\u6d69\u53f2\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u897f\u539f\u5e83\u53f2\uff0c\u7551\u4e2d\u3000\u8c4a\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u4e2d\u6751\u3000\u900f\uff0c\u5e73\u91ce\u3000\u8061\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aThe analysis of biglycan expression in human lung cancer\uff0c\u7b2c5\u56de\u304c\u3093\u3068\u4ee3\u8b1d\u7814\u7a76\u4f1a in \u672d\u5e4c\uff0c2017.7.14\uff08\u672d\u5e4c\uff09<\/li>\n
                  19. \u83ca\u5730\u3000\u592e, \u9593\u77f3\u5948\u6e56, \u79cb\u5c71\u5ee3\u8f14, Randa Ibrahim Hassan Dawood, \u571f\u5c4b\u90a6\u5f66, \u4e38\u5c71\u3000\u899a, \u5b89\u90e8\u5d07\u91cd, \u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u6797\u3000\u900f, \u98f4\u7530\u3000\u8981, \u67cf\u6728\u3000\u660e, \u677e\u91ce\u5409\u5b8f, \u7be0\u539f\u4fe1\u96c4,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aAnalysis of multidrug resistant transporter expression in tumor blood vessels of urothelial carcinoma during chemotherapy\uff0c\u7b2c5\u56de\u304c\u3093\u3068\u4ee3\u8b1d\u7814\u7a76\u4f1a in \u672d\u5e4c\uff0c2017.7.14\uff08\u672d\u5e4c\uff09<\/li>\n
                  20. Dorcas A. Annan, Maishi N., Soga T., Hojo T., Randa Dawood, Hida Y., Kikuchi H.,\u00a0Hida K.<\/u>\uff1aTumor endothelial cells tolerate low pH environments by upregulating proton transporters\uff0c\u7b2c5\u56de\u304c\u3093\u3068\u4ee3\u8b1d\u7814\u7a76\u4f1a in \u672d\u5e4c\uff0c2017.7.13\uff08\u672d\u5e4c\uff09<\/li>\n
                  21. \u9593\u77f3\u5948\u6e56\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308bBiglycan\u306e\u5206\u6ccc\u3092\u4ecb\u3057\u305f\u304c\u3093\u306e\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c\uff12\u56de\u53e3\u8154\u533b\u79d1\u5b66\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\u7814\u7a76\u4f1a\uff0c2017.3.5\uff08\u5c71\u5f62\uff09<\/li>\n
                  22. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5e73\u621028\u5e74\u5ea6\u91d1\u6ca2\u5927\u5b66\u304c\u3093\u9032\u5c55\u5236\u5fa1\u7814\u7a76\u6240\u5171\u540c\u5229\u7528\u30fb\u5171\u540c\u7814\u7a76\u62e0\u70b9\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff0c\u201c\u9ad8\u8ee2\u79fb\u6027\u816b\u760dmiR\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308b\u85ac\u5264\u8010\u6027\u8a98\u5c0e\u201d\uff0c2017.2.14\uff08\u91d1\u6ca2\uff09<\/li>\n<\/ol>\n

                    2016<\/h4>\n
                      \n
                    1. \u67f3\u8c37\u7f8e\u6c99\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCorrelation between CXCR7 expression of blood vessels and clinicopathological features in oral squamous cell carcinoma\uff0c\u7b2c24\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2016.12.10\uff08\u9577\u5d0e\uff09<\/li>\n
                    2. \u83ca\u5730\u3000\u592e\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u68ee\u672c\u771f\u5f18\uff0c\u67f3\u8c37\u7f8e\u6c99\uff0c\u571f\u5c4b\u90a6\u5f66\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u6797\u3000\u900f\uff0c\u98f4\u7530\u3000\u8981\uff0c\u67cf\u6728\u3000\u660e\uff0c\u7530\u4e2d\u4f38\u54c9\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aP-glycoprotein expression dynamics in tumor blood vessels of urothelial carcinoma during chemotherapy,\u7b2c24\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2016.12.10\uff08\u9577\u5d0e\uff09<\/li>\n
                    3. \u67f3\u8c37\u7f8e\u6c99\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u30de\u30fc\u30ab\u30fcCXCR7\u306e\u767a\u73fe\u89e3\u6790\uff0c\u7b2c49\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c\u7b2c7\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2016.10.18\uff08\u672d\u5e4c\uff09<\/li>\n
                    4. Annan Dorcas Akuba Muhyia\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u66fd\u6211\u670b\u7fa9\uff0c\u5317\u689d\u656c\u4e4b\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u83ca\u5730\u3000\u592e\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor endothelial cells are resistant to acidic environments\uff0c\u7b2c49\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c\u7b2c7\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2016.10.18\uff08\u672d\u5e4c\uff09<\/li>\n
                    5. \u83ca\u5730\u3000\u592e\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u571f\u5c4b\u90a6\u5f66\uff0c\u4e38\u5c71\u3000\u899a\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u6797\u3000\u900f\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6297\u764c\u5264\u6cbb\u7642\u524d\u5f8c\u306e\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306eP-glycoprotein \u767a\u73fe\u5909\u5316\uff0c\u7b2c7\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2016.10.18\uff08\u672d\u5e4c\uff09<\/li>\n
                    6. \u68ee\u672c\u771f\u5f18, \u9ce5\u5c45\u3061\u3055\u307b, \u5ddd\u672c\u6cf0\u8f14, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5409\u5ca1\u7950\u4eae, \u843d\u8c37\u5b5d\u5e83, \u67f3\u8c37\u7f8e\u6c99, \u83ca\u5730\u3000\u592e, \u5317\u5ddd\u5584\u653f, \u912d\u6f22\u3000\u5fe0, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760d\u30a8\u30af\u30bd\u30bd\u30fc\u30e0miRNA\u306f\u8840\u7ba1\u5185\u76ae\u306eIL6\u3092\u8a98\u5c0e\u3057\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u3078\u306e\u8010\u6027\u3092\u8a98\u5c0e\u3059\u308b\uff0c\u7b2c7\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff0c2016.10.18\uff08\u672d\u5e4c\uff09<\/li>\n
                    7. \u67f3\u8c37\u7f8e\u6c99\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u30de\u30fc\u30ab\u30fcCXCR7\u306e\u767a\u73fe\u89e3\u6790\uff0c\u7b2c49\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2016.10.15\uff08\u672d\u5e4c\uff09<\/li>\n
                    8. \u83ca\u5730\u3000\u592e\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u68ee\u672c\u771f\u5f18\uff0c\u67f3\u8c37\u7f8e\u6c99\uff0c\u5bae\u5cf6\u76f4\u4eba\uff0c\u571f\u5c4b\u90a6\u5f66\uff0c\u4e38\u5c71\u3000\u899a\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u6797\u3000\u900f\uff0c\u98f4\u7530\u3000\u8981\uff0c\u677e\u672c\u9686\u5150\uff0c\u67cf\u6728\u3000\u660e\uff0c\u51fa\u6751\u5b5d\u7fa9\uff0c\u6d25\u7530\u771f\u5bff\u7f8e\uff0c\u7530\u4e2d\u4f38\u54c9\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6297\u764c\u5264\u6cbb\u7642\u524d\u5f8c\u306e\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306eP-glycoprotein\u767a\u73fe\u5909\u5316\uff0c\u7b2c49\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2016.10.15\uff08\u672d\u5e4c\uff09<\/li>\n
                    9. Annan Dorcas Akuba Muhyia\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u66fd\u6211\u670b\u7fa9\uff0c\u5317\u689d\u656c\u4e4b\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u83ca\u5730\u3000\u592e\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor endothelial cells are resistant to acidic environments\uff0c\u7b2c49\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2016.10.15\uff08\u672d\u5e4c\uff09<\/li>\n
                    10. \u9593\u77f3\u5948\u6e56\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5409\u5ca1\u7950\u4eae\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u67f3\u8c37\u7f8e\u6c99\uff0c\u68ee\u672c\u771f\u5f18\uff0c\u83ca\u5730\u3000\u592e\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760dmiR\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bIL-6\u3092\u4ecb\u3057\u305f\u85ac\u5264\u8010\u6027\u8a98\u5c0e\uff0c\u7b2c49\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2016.10.15\uff08\u672d\u5e4c\uff09<\/li>\n
                    11. \u83ca\u5730\u3000\u592e\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u571f\u5c4b\u90a6\u5f66\uff0c\u4e38\u5c71\u3000\u899a\uff0c\u5b89\u90e8\u5d07\u91cd\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u539f\u6797\u3000\u900f\uff0c\u677e\u91ce\u5409\u5b8f\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6297\u764c\u5264\u6cbb\u7642\u524d\u5f8c\u306e\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306eP-glycoprotein \u767a\u73fe\u5909\u5316\uff0c\u7b2c75\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2016.10.7\uff08\u6a2a\u6d5c\uff09<\/li>\n
                    12. Dorcas A Annan, Maishi N., Soga T., Hida Y., Torii C., Kikuchi H.,\u00a0Hida K.<\/u>\uff1aTumor endothelial cells are resistant to acidic environments\uff0c\u7b2c75\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2016.10.7\uff08\u6a2a\u6d5c\uff09<\/li>\n
                    13. \u9593\u77f3\u5948\u6e56\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308bbiglycan\u306e\u5206\u6ccc\u3092\u4ecb\u3057\u305f\u304c\u3093\u306e\u8ee2\u79fb\u4fc3\u9032\uff0c\u5e73\u621028\u5e74\u5ea6\u65b0\u5b66\u8853\u9818\u57df\u7814\u7a76\u300c\u5b66\u8853\u7814\u7a76\u652f\u63f4\u57fa\u790e\u5f62\u6210\u3010\u5148\u7aef\u30e2\u30c7\u30eb\u52d5\u7269\u652f\u63f4\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3011\u300d\u82e5\u624b\u652f\u63f4\u6280\u8853\u8b1b\u7fd2\u4f1a\uff0c2016.9.17\uff08\u84fc\u79d1\uff09<\/li>\n
                    14. \u68ee\u672c\u771f\u5f18\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760dmiR\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bIL-6\u3092\u4ecb\u3057\u305f\u85ac\u5264\u8010\u6027\u8a98\u5c0e\uff0c\u7b2c8\u56de\u65e5\u672cRNA-i\u7814\u7a76\u4f1a\uff0c2016.9.2\uff08\u5e83\u5cf6\uff09<\/li>\n
                    15. \u83ca\u5730\u3000\u592e\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6297\u764c\u5264\u6cbb\u7642\u524d\u5f8c\u306e\u5c3f\u8def\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306eP-glycoprotein\u767a\u73fe\u5909\u5316\uff0c\u7b2c25\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\uff0c2016.7.21\uff08\u7c73\u5b50\uff09<\/li>\n
                    16. \u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308bbiglycan\u306e\u5206\u6ccc\u3092\u4ecb\u3057\u305f\u304c\u3093\u306e\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c25\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\uff0c2016.7.21\uff08\u7c73\u5b50\uff09<\/li>\n
                    17. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5206\u6ccc\u5c0f\u80demiRNA\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u306e\u85ac\u5264\u8010\u6027\u8a98\uff0c\u7b2c2\u56de\u8840\u7ba1\u751f\u7269\u82e5\u624b\u7814\u7a76\u4f1a\uff0c2016.3.4\uff08\u4ed9\u53f0\uff09<\/li>\n<\/ol>\n

                      2015<\/h4>\n
                        \n
                      1. \u9593\u77f3\u5948\u6e56, \u5927\u5834\u96c4\u4ecb, \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6d5c\u7530\u6df3\u4e00, \u5317\u672c\u5b97\u5b50, Mohammad Alam T., \u5c71\u672c\u548c\u5e78, \u5ddd\u672c\u6cf0\u8f14, \u4e95\u4e0a\u8fb2\u592b\u7537, \u6b66\u5bcc\u7d39\u4fe1, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>. \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308bbiglycan \u306e\u5206\u6ccc\u3092\u4ecb\u3057\u305f\u304c\u3093\u306e\u8ee2\u79fb\u4fc3\u9032.\u201d \u7b2c23\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 12.11\uff08\u795e\u6238\uff09<\/li>\n
                      2. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0cMohammad T Alam\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u85e4\u6fa4\u4fca\u660e\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aROS \u306b\u3088\u308bbiglycan \u767a\u73fe\u8a98\u5c0e\u3092\u4ecb\u3057\u305f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u8840\u7ba1\u65b0\u751f\u80fd\u4ea2\u9032\uff0c\u7b2c74\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2015.10.10\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                      3. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6238\u585a\u9756\u5247\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5357\u3000\u656c\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760dmiRNA \u306fIL-6 \u306a\u3089\u3073\u306bALDH \u306e\u767a\u73fe\u4ea2\u9032\u3092\u4ecb\u3057\u3066\u8840\u7ba1\u5185\u76ae\u306b\u85ac\u5264\u8010\u6027\u3092\u8a98\u5c0e\u3059\u308b\uff0c\u7b2c74\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2015.10.10\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                      4. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5317\u672c(\u6c38\u5c3e\uff09\u5b97\u5b50\uff0cMohammad Alam T.\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306fbiglycan \u306e\u5206\u6ccc\u3092\u4ecb\u3057\u3066\u304c\u3093\u306e\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b\uff0c\u7b2c74\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2015.10.8\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                      5. Annan Dorcas A., \u9593\u77f3\u5948\u6e56\uff0c\u5317\u689d\u656c\u4e4b\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0cMohammad T Alam.\uff0cHabiba Umma\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor Endothelial cell-secreted protein activates a DNA damage response\uff0c\u7b2c112\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2015.9.12\uff08\u672d\u5e4c\uff09<\/li>\n
                      6. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6238\u585a\u9756\u5247\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5357\u3000\u656c\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760dmiR\u306b\u3088\u3089\u3046\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bIL-6\u3092\u4ecb\u3057\u305f\u85ac\u5264\u8010\u6027\u8a98\u5c0e\uff0c\u7b2c112\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2015.9.12\uff08\u672d\u5e4c\uff09<\/li>\n
                      7. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5317\u672c\u5b97\u5b50\uff0cAlam Mohammad Towfik\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306fbiglycan\u306e\u5206\u6ccc\u3092\u4ecb\u3057\u3066\u304c\u3093\u306e\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b\uff0c\u7b2c26\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff0c2015.7.31\uff08\u672d\u5e4c\uff09<\/li>\n
                      8. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6238\u585a\u9756\u5247\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u9ad8\u8ee2\u79fb\u6027\u816b\u760dmiRNA\u306fIL-6\u306a\u3089\u3073\u306bALDH\u306e\u767a\u73fe\u4ea2\u9032\u3092\u4ecb\u3057\u3066\u8840\u7ba1\u5185\u76ae\u306b\u85ac\u5264\u8010\u6027\u3092\u8a98\u5c0e\u3059\u308b\uff0c\u7b2c26\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff0c2015.7.31\uff08\u672d\u5e4c\uff09<\/li>\n
                      9. Alam Mohammad Towfik\uff0cNagao-Kitamoto H., Ohga N., Akiyama K., Maishi N., Shinohara N., Taketomi A. Shindoh M., Hida Y.,\u00a0Hida K.<\/u>\uff1aSuprabasin as a novel tumor endothelial cell marker\uff0c\u7b2c26\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff0c2015.7.31\uff08\u672d\u5e4c\uff09<\/li>\n
                      10. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u85e4\u6fa4\u4fca\u660e\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u6d3b\u6027\u9178\u7d20\u7a2e\u306b\u3088\u308bBiglycan\u767a\u73fe\u8a98\u5c0e\u3092\u4ecb\u3057\u305f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u8840\u7ba1\u65b0\u751f\u80fd\u4ea2\u9032\uff0c\u7b2c26\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\uff0c2015.7.31\uff08\u672d\u5e4c\uff09<\/li>\n
                      11. \u9593\u77f3\u5948\u6e56\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306fbiglycan\u306e\u5206\u6ccc\u3092\u4ecb\u3057\u3066\u304c\u3093\u306e\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b\uff0c\u7b2c24\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\uff0c2015.7.23\uff08\u5927\u962a\uff09<\/li>\n
                      12. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3044\u3066\uff0c\u816b\u760d\u7531\u6765\u306emiRX \u306b\u3088\u308a\u8840\u7ba1\u5185\u76ae\u306fIL-6 \u3092\u30aa\u30fc\u30c8\u30af\u30e9\u30a4\u30f3\u3067\u5229\u7528\u3057\uff0c\u85ac\u5264\u8010\u6027\u3084\u5e79\u7d30\u80de\u6027\u3092\u7372\u5f97\u3057\u3066\u3044\u308b\uff0c\u7b2c69\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2015.5.14\uff08\u5927\u962a\uff09<\/li>\n
                      13. \u9593\u77f3\u5948\u6e56\uff1aTumor endothelial cells instigate metastasis of indolent tumors, \u7b2c1\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u82e5\u624b\u7814\u7a76\u4f1a, 2015.2.7\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n

                        2014<\/h4>\n
                          \n
                        1. \u9593\u77f3\u5948\u6e56\uff1aTumor endothelial cells instigate metastasis of indolent tumors, IGM\u30ea\u30b5\u30fc\u30c1\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\uff08\u7b2c6\u56deIGM\u7814\u7a76\u4ea4\u6d41\u4f1a\uff09\uff0c2014.12.25\uff08\u672d\u5e4c\uff09<\/li>\n
                        2. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c1\u56de\u516d\u7532\u533b\u5b66\u7814\u7a76\u4f1a\uff0c2014.11.7\uff08\u795e\u6238\uff09<\/li>\n
                        3. \u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u816b\u760d\u7d30\u80de\u306e\u76f8\u4e92\u4f5c\u7528\uff0c\u7b2c56\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30fb\u7dcf\u4f1a\uff0c2014.9.26\uff08\u798f\u5ca1\uff09<\/li>\n
                        4. \u79cb\u91ce\u6587\u81e3\uff0c\u4e2d\u5c71\u5bdb\u5c1a\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff0cKlagsbrun M.\uff1aNetrin-1\u306fmedulloblastoma\u306e\u6d78\u6f64\uff0c\u5897\u6b96\u3092\u4fc3\u9032\u3059\u308b\uff0c\u7b2c73\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2014.9.25\uff08\u6a2a\u6d5c\uff09<\/li>\n
                        5. \u5c71\u7530\u5065\u53f8\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u9ad8\u6a4b\u5178\u5f66\uff0c\u795e\u5c71\u4fca\u54c9\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6b66\u51a8\u7d39\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCXCR7\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u7642\u6cd5\u306e\u53ef\u80fd\u6027\uff0c\u7b2c73\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2014.9.25\uff08\u6a2a\u6d5c\uff09<\/li>\n
                        6. \u5927\u8cc0\u5247\u5b5d\uff0c\u8fd1\u85e4\u7f8e\u4e5f\u5b50\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5185\u4f4e\u9178\u7d20\u74b0\u5883\u3068\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027\u306e\u95a2\u9023\uff0c\u7b2c73\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2014.9.25\uff08\u6a2a\u6d5c\uff09<\/li>\n
                        7. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c110\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2014.9.13\uff08\u672d\u5e4c\uff09<\/li>\n
                        8. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u5ee3\u6d0b\u4e00\uff0c\u5c0f\u91ce\u8ca2\u4f38\uff0c\u6238\u585a\u9756\u5247\uff0c\u677e\u91ce\u5409\u5f18\uff0c\u5317\u5ddd\u5584\u653f\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u4f50\u85e4\u9756\u53f2\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50\u3068\u3057\u3066\u306eVasohibin-1\uff0c\u7b2c110\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2014.9.13\uff08\u672d\u5e4c\uff09<\/li>\n
                        9. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u85e4\u6fa4\u4fca\u660e\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aROS\u304c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u53ca\u307c\u3059\u5f71\u97ff\uff0c\u7b2c110\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2014.9.13\uff08\u672d\u5e4c\uff09<\/li>\n
                        10. \u9593\u77f3\u5948\u6e56, \u5927\u5834\u96c4\u4ecb, \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6d5c\u7530\u6df3\u4e00, \u5c71\u672c\u548c\u5e78, \u5ddd\u672c\u6cf0\u8f14,\u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308b\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c79\u56de\u65e5\u672c\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u30fb\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2014.6.19-20\uff08\u672d\u5e4c\uff09<\/li>\n
                        11. \u5b89\u6c38\u8ce2\u53f2\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0cAlam Mohammad Towfik\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u306b\u304a\u3051\u308b\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u95a2\u9023\u56e0\u5b50Biglycan \u306e\u767a\u73fe\u3068\u6a5f\u80fd\uff0c\u7b2c103\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c4.26\uff08\u5e83\u5cf6\uff09<\/li>\n
                        12. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c103\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c4.24\uff08\u5e83\u5cf6\uff09<\/li>\n
                        13. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u689d\u656c\u4e4b,\u5927\u5ee3\u6d0b\u4e00\uff0c\u5c0f\u91ce\u8ca2\u4f38,\u6238\u585a\u9756\u5247\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u4f50\u85e4\u9756\u53f2, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50\u3068\u3057\u3066\u306eVasohibin-1\uff0c\u7b2c103\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c4.24\uff08\u5e83\u5cf6\uff09<\/li>\n<\/ol>\n

                          2013<\/h4>\n
                            \n
                          1. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u689d\u656c\u4e4b,\u5927\u5ee3\u6d0b\u4e00\uff0c\u5c0f\u91ce\u8ca2\u4f38, \u6238\u585a\u9756\u5247\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u4f50\u85e4\u9756\u53f2,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50Vasohibin-1\uff0c\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
                          2. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik,\u3000\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3092\u6a19\u7684\u3068\u3057\u305f\u30e1\u30c8\u30ed\u30ce\u30df\u30c3\u30af\u30b1\u30e2\u30bb\u30e9\u30d4\u30fc\u3068P-gp\u963b\u5bb3\u5264\u306e\u4f75\u7528\u7642\u6cd5\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e\uff0c\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
                          3. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f79\u5272\uff0c\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
                          4. \u5927\u6751\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u9593\u77f3\u5948\u6e56\uff0cAlam MohammadTowfik\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u98ef\u7530\u9806\u4e00\u90ce\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aALDH\u967d\u6027\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c46\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff0c2013.10.12\uff08\u672d\u5e4c\uff09<\/li>\n
                          5. \u9ce5\u5c45\u3061\u3055\u307b\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5317\u689d\u656c\u4e4b, \u5927\u5ee3\u6d0b\u4e00\uff0c\u5c0f\u91ce\u8ca2\u4f38, \u6238\u585a\u9756\u5247\uff0c\u912d\u3000\u6f22\u5fe0\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u4f50\u85e4\u9756\u53f2,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u764c\u306b\u304a\u3051\u308b\u65b0\u898f\u4e88\u5f8c\u56e0\u5b50Vasohibin-1\u306e\u767a\u73fe\u89e3\u6790\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
                          6. \u5ddd\u672c\u6cf0\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1amicrovesicles\u3092\u4ecb\u3057\u3066\u816b\u760d\u7d30\u80de\u7531\u6765\u306emiRNA\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3078\u8f38\u9001\u3055\u308c\u308b\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
                          7. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aP-gp\u963b\u5bb3\u5264\u306f\u30e1\u30c8\u30ed\u30ce\u30df\u30c3\u30af\u30b1\u30e2\u30bb\u30e9\u30d4\u30fc\u306e\u8840\u7ba1\u65b0\u751f\u963b\u5bb3\u52b9\u679c\u3092\u5f37\u3081\u308b\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
                          8. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d,\u79cb\u5c71\u5ee3\u8f14,\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u3088\u308b\u304c\u3093\u8ee2\u79fb\u4fc3\u9032\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.4\uff08\u6a2a\u6d5c\uff09<\/li>\n
                          9. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50,\u3000\u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u85e4\u6fa4\u4fca\u660e\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u9178\u7d20\u30fb\u4f4e\u6804\u990a\u5faa\u74b0\u306b\u3088\u308bROS\u306e\u84c4\u7a4d\u304c\u53ca\u307c\u3059TEC\u3078\u306e\u5f71\u97ff\uff0c\u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                          10. \u5c71\u7530\u5065\u53f8, \u9593\u77f3\u5948\u6e56, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u9032\u85e4\u6b63\u4fe1\uff0c\u9ad8\u6a4b\u5178\u5f66, \u795e\u5c71\u4fca\u54c9, \u6a0b\u7530\u6cf0\u6d69\uff0c\u6b66\u51a8\u7d39\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCXCR7\u306e\u6628\u65e5\u89e3\u6790, \u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                          11. Alam Mohammad Towfik, \u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u7be0\u539f\u4fe1\u96c4, \u91ce\u3005\u6751\u514b\u4e5f\uff0c\u571f\u5c4b\u90a6\u5f66, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aSBSN is a novel Tumor Endothelial Cell marker, \u7b2c72\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2013.10.3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                          12. \u5ddd\u672c\u6cf0\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived miRNA is transported to endothelial cells by microvesicles\uff0c\u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.27\uff08\u5927\u962a\uff09<\/li>\n
                          13. \u5c71\u7530\u5065\u53f8\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u9ad8\u6a4b\u5178\u5f66\uff0c\u795e\u5c71\u4fca\u54c9, \u6b66\u51a8\u7d39\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCXCR7 \u306e\u6a5f\u80fd\u89e3\u6790, \u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
                          14. \u5317\u689d\u656c\u4e4b, \u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50, \u89d2\u8c37\u3000\u77b3, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u85e4\u6fa4\u4fca\u660e,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u9178\u7d20\u30fb\u4f4e\u6804\u990a\u306b\u3088\u308a\u8a98\u5c0e\u3055\u308c\u308bROS\u304c\u53ca\u307c\u3059\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u306e\u5f71\u97ff\uff0c\u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
                          15. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f79\u5272\uff0c\u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
                          16. \u6c38\u5c3e\u5b97\u5b50, Alam Mohammad Towfik\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u7be0\u539f\u4fe1\u96c4, \u6b66\u51a8\u7d39\u4fe1, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aSBSN is a novel Tumor Endothelial Cell maker, \u7b2c21\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2013.9.26\uff08\u5927\u962a\uff09<\/li>\n
                          17. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3057\u305fMetronomic Chemotherapy\u3068P-gp\u963b\u5bb3\u5264\u306e\u4f75\u7528\u7642\u6cd5\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e\uff0c\u7b2c108\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2013.9.21\uff08\u65ed\u5ddd\uff09<\/li>\n
                          18. \u5ddd\u672c\u6cf0\u8f14\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5c0f\u5742\u5c55\u6176\uff0c\u843d\u8c37\u5b5d\u5e83\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived miRNA is transported to endothelial cells by microvesicles\uff0c\u7b2c108\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2013.9.21\uff08\u65ed\u5ddd\uff09<\/li>\n
                          19. \u5317\u689d\u656c\u4e4b\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u89d2\u8c37\u77b3, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69, \u85e4\u6fa4\u4fca\u660e,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u6804\u990a\u306b\u3088\u308a\u8a98\u5c0e\u3055\u308c\u308bROS\u304c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u53ca\u307c\u3059\u5f71\u97ff\uff0c\u7b2c108\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff0c2013.9.21\uff08\u65ed\u5ddd\uff09<\/li>\n
                          20. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aP-gp \u963b\u5bb3\u5264\u306f\u30d1\u30af\u30ea\u30bf\u30ad\u30bb\u30eb\u306e\u6297\u816b\u760d\u52b9\u679c\u3092\u5897\u5f37\u3059\u308b, \u7b2c22\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a,2013.7.12\uff08\u677e\u672c\uff09<\/li>\n
                          21. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik\uff0c\u5927\u6751\u3000\u77b3\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5f79\u5272\uff0c\u7b2c22\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a,2013.7.12\uff08\u677e\u672c\uff09<\/li>\n
                          22. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5927\u6751\u3000\u77b3\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u4e0e\uff0c\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
                          23. Alam Mohammad Towfik, \u5927\u8cc0\u5247\u5b5d\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan\u306f\u816b\u760d\u8840\u7ba1\u306b\u304a\u3051\u308b\u65b0\u898f\u8840\u7ba1\u65b0\u751f\u95a2\u9023\u56e0\u5b50\u3067\u3042\u308b, \u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
                          24. \u5927\u6751\u3000\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik, \u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u98ef\u7530\u9806\u4e00\u90ce\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aALDH\u967d\u6027\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
                          25. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik,\u3000\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3057\u305fMetronomic Chemotherapy\u3068P-gp\u963b\u5bb3\u5264\u306e\u4f75\u7528\u7642\u6cd5\u306e\u6709\u52b9\u6027\u306e\u691c\u8a0e\uff0c\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.7\uff08\u672d\u5e4c\uff09<\/li>\n
                          26. \u5c71\u7530\u5065\u53f8\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0cAlam Mohammad Towfik, \u5927\u6751\u3000\u77b3\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9ad8\u6a4b\u5178\u5f66\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6b66\u51a8\u7d39\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCXCR7 \u306e\u6a5f\u80fd\u89e3\u6790,\u7b2c102\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2013.6.6\uff08\u672d\u5e4c\uff09<\/li>\n
                          27. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik, \u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6751\u3000\u77b3\uff0c\u5c71\u7530\u5065\u53f8\uff0c\u9ce5\u5c45\u3061\u3055\u307b\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u30d9\u30e9\u30d1\u30df\u30eb\u306f\u30d1\u30af\u30ea\u30bf\u30ad\u30bb\u30eb\u306e\u6297\u816b\u760d\u52b9\u679c\u3092\u5897\u5f37\u3059\u308b\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.24\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
                          28. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.24\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
                          29. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u7d30\u80de\u7531\u6765\u306emicrovesicle\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306eproangiogenic phenotype\u3092\u5f15\u304d\u8d77\u3053\u3059\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.23\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
                          30. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u8cc0\u5247\u5b5d,\u3000\u79cb\u5c71\u5ee3\u8f14\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6751\u3000\u77b3\uff0c\u4e95\u4e0a\u8fb2\u592b\u7537\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u308f\u308a\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.23\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n
                          31. \u5927\u6751\u3000\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0cAlam Mohammad Towfik, \u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u98ef\u7530\u9806\u4e00\u90ce, \u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aALDH\u967d\u6027\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\uff0c\u7b2c67\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0c2013.5.23\uff08\u5b87\u90fd\u5bae\uff09<\/li>\n<\/ol>\n

                            2012<\/h4>\n
                              \n
                            1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCrosstalk between tumor endothelial cells and tumor cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
                            2. \u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d,\u3000\u79cb\u5c71\u5ee3\u8f14\uff0c\u5e73\u7530\u5c1a\u4e5f\uff0c\u5317\u539f\u79c0\u6cbb\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
                            3. \u5927\u8cc0\u5247\u5b5d\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c \u5e73\u91ce\u3000\u8061, \u7be0\u539f\u4fe1\u96c4\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u00a0*<\/u>\u6a0b\u7530\u4eac\u5b50<\/u>\uff0c: Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
                            4. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u91ce\u3005\u6751\u514b\u4e5f\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\u00a0: The role of Lysyl oxidase on proangiogenic phenotypes of tumor endothelial cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
                            5. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: The role of tumor endothelial cells in tumor metastasis, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
                            6. \u5927\u6751\u3000\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u98ef\u7530\u9806\u4e00\u90ce\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Characterization of Aldehyde dehydrogenase(ALDH) positive tumor endothelial cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
                            7. \u571f\u5c4b\u90a6\u5f66\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c0f\u91ce\u5bfa\u96c4\u4e00\u90ce\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u85e4\u6c5f\u3000\u5b66\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u91ce\u3005\u6751\u514b\u4e5f\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u30d7\u30ed\u30b9\u30bf\u30b5\u30a4\u30af\u30ea\u30f3\u53d7\u5bb9\u4f53\u306f\u8840\u7ba1\u65b0\u751f\u3092\u30aa\u30fc\u30c8\u30af\u30e9\u30a4\u30f3\u306b\u4fc3\u9032\u3059\u308b\uff0c\u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff0c2012.9.19\uff08\u672d\u5e4c\uff09<\/li>\n
                            8. \u5ddd\u672c\u6cf0\u8f14, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u5e73\u7530\u5c1a\u4e5f, \u5317\u539f\u79c0\u6cbb, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-Derived Microvesicles Induce Proangiogenic Phenotype in Endothelial Cells via Endocytosis, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a), 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
                            9. \u9593\u77f3\u5948\u6e56, \u5927\u5834\u96c4\u4ecb, \u5c71\u672c\u548c\u5e78, \u5927\u8cc0\u5247\u5b5d, \u6d5c\u7530\u6df3\u4e00, \u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u6751\u3000\u77b3, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u308f\u308a, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff09, 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
                            10. \u5927\u8cc0\u5247\u5b5d, \u5c71\u672c\u548c\u5e78, \u6a0b\u7530\u6cf0\u6d69, \u9593\u77f3\u5948\u6e56, \u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u9032\u85e4\u6b63\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan is an autocrine angiogenic factor of tumour endothelial cells, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff09, 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
                            11. \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u9032\u85e4\u6b63\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5185\u4f4e\u9178\u7d20\u74b0\u5883\u3068\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027\u306e\u95a2\u9023, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff09, 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
                            12. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u9593\u77f3\u5948\u6e56, \u79cb\u5c71\u5ee3\u8f14, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6751\u3000\u77b3, \u9032\u85e4\u6b63\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u306e\u7279\u6027\u89e3\u6790, \u7b2c23\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2012.8.31\uff08\u6771\u4eac\uff09<\/li>\n
                            13. \u9593\u77f3\u5948\u6e56, \u5927\u5834\u96c4\u4ecb, \u5c71\u672c\u548c\u5e78, \u5927\u8cc0\u5247\u5b5d, \u6d5c\u7530\u6df3\u4e00, \u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u6751\u3000\u77b3, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u308f\u308a, \u7b2c21\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2012.7.12\uff08\u5e83\u5cf6\uff09<\/li>\n
                            14. \u5927\u6751\u3000\u77b3, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u5ddd\u672c\u6cf0\u8f14, \u98ef\u7530\u9806\u4e00\u90ce, \u9032\u85e4\u6b63\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bALDH\u306e\u767a\u73fe\u89e3\u6790\u3068ALDH\u9ad8\u6d3b\u6027\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790, \u7b2c21\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2012.7.12\uff08\u5e83\u5cf6\uff09<\/li>\n
                            15. \u5ddd\u672c\u6cf0\u8f14, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis, \u7b2c28\u56de\u65e5\u672cDDS\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.7.4\uff08\u672d\u5e4c\uff09<\/li>\n
                            16. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u9032\u85e4\u6b63\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u306e\u7279\u6027\u89e3\u6790, \u7b2c28\u56de\u65e5\u672cDDS\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.7.3\uff08\u672d\u5e4c\uff09<\/li>\n
                            17. \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u5b9a\u672c\u572d\u5f18, \u77f3\u5ddd\u4fee\u5e73, \u9593\u77f3\u5948\u6e56, \u79cb\u91ce\u6587\u81e3, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u677e\u7530\u5f69, \u4e95\u4e0a\u8fb2\u592b\u7537, \u9032\u85e4\u6b63\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308bVEGF\u30b7\u30b0\u30ca\u30eb\u3092\u4ecb\u3057\u305fMDR1\u306e\u767a\u73fe\u4ea2\u9032\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066, \u7b2c66\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.5.18\uff08\u5e83\u5cf6\uff09<\/li>\n
                            18. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5b9a\u672c\u572d\u5f18\uff0c\u77f3\u5ddd\u4fee\u5e73\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308bVEGF\u30b7\u30b0\u30ca\u30eb\u3092\u4ecb\u3057\u305fMDR1\u306e\u767a\u73fe\u4ea2\u9032\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066\uff0c\u7b2c101\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\uff0c2012.4.28\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n

                              2011<\/h4>\n
                                \n
                              1. \u5927\u8cc0\u5247\u5b5d\uff0c\u77f3\u5ddd\u4fee\u5e73\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5b9a\u672c\u572d\u5f18\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\u00a0: Heterogeneity of Tumor Endothelial Cells:Comparison between Tumor Endothelial Cells Isolated from Highly Metastatic and Low Metastatic Tumors, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
                              2. \u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Tumor-derived Microvesicles Promote Cell Motility and Tubeformation via Endocytosis in Endothelial Cells, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
                              3. \u5927\u6fa4\u5d07\u5b8f\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u91ce\u3005\u6751\u514b\u4e5f\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: The role of Lysyl oxidase on abnormal phenotypes of tumor endothelial cells, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
                              4. \u5c71\u672c\u548c\u5e78\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u52a0\u8cc0\u57fa\u77e5\u4e09\uff0c\u5e73\u91ce\u3000\u8061, \u7be0\u539f\u4fe1\u96c4\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\u00a0: Biglycan is an angiogenic factor stimulating cell migration of tumor endothelium, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
                              5. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5b9a\u672c\u572d\u5f18\uff0c \u77f3\u5ddd\u4fee\u5e73\uff0c\u9593\u77f3\u5948\u6e56\uff0c \u79cb\u91ce\u6587\u81e3, \u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u5927\u6751\u3000\u77b3\uff0c\u677e\u7530\u3000\u5f69\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Tumor endothelial cells aquire drug resistance by MDR1 upregulation via VEGF signaling in tumor microenvironment, \u7b2c19\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2011.12.8-10\uff08\u6771\u4eac\uff09<\/li>\n
                              6. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5ddd\u672c\u6cf0\u8f14, \u9032\u85e4\u6b63\u4fe1,\u00a0\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u304b\u3089\u5206\u96e2\u3055\u308c\u305f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u6bd4\u8f03\u89e3\u6790, \u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7570\u5e38\u6027\u306e\u7372\u5f97, \u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2011.10.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              7. \u9593\u77f3\u5948\u6e56\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u5834\u96c4\u4ecb\u3001\u6d5c\u7530\u6df3\u4e00\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u5c71\u672c\u548c\u5e78\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u304c\u3093\u8ee2\u79fb\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012011.10.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              8. \u5927\u6fa4\u5d07\u5b8f\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u5317\u5c71\u548c\u5b50\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5c71\u672c\u548c\u5e78\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bLysyl oxidase\u306e\u6a5f\u80fd\u89e3\u6790\u3001\u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012011.10.5\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              9. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u6a0b\u7530\u6cf0\u6d69\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7570\u5e38\u6027\u306e\u7372\u5f97\u3001\u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012011.10.4\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              10. \u79cb\u5c71\u5ee3\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u5b9a\u672c\u572d\u5f18\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5c71\u672c\u548c\u5e78\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u764c\u7d30\u80de\u57f9\u990a\u4e0a\u6e05\u306b\u3088\u308b\u6b63\u5e38\u8840\u7ba1\u5185\u76ae\u306e\u85ac\u5264\u62b5\u6297\u6027\u306e\u7372\u5f97\u3001\u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              11. \u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u79cb\u5927\u8cc0\u5247\u5b5d\u3001\u5c71\u5ee3\u8f14\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5c71\u672c\u548c\u5e78\u3001\u5927\u6751\u77b3\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u4f4e\u9178\u7d20\u74b0\u5883\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u53ca\u307c\u3059\u5f71\u97ff\u3001\u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              12. \u5c71\u672c\u548c\u5e78\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5317\u5c71\u548c\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u52a0\u8cc0\u57fa\u77e5\u4e09\u3001\u5e73\u91ce\u8061\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bBiglycan\u306e\u6a5f\u80fd\u89e3\u6790\u3001\u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              13. \u5ddd\u672c\u6cf0\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u9593\u77f3\u5948\u6e56\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5c71\u672c\u548c\u5e78\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u7531\u6765microvesicles\u304c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u904b\u52d5\u80fd\u3068\u7ba1\u8154\u5f62\u6210\u80fd\u3092\u4ea2\u9032\u3055\u305b\u308b\u3001\u7b2c70\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012011.10.3\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                              14. \u9593\u77f3\u5948\u6e56\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u304c\u3093\u8ee2\u79fb\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u7b2c53\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30fb\u7dcf\u4f1a\u30012011.10.1\uff08\u5c90\u961c\uff09<\/li>\n
                              15. \u79cb\u5c71\u5ee3\u8f14\u3001\u9593\u77f3\u5948\u6e56\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u7d30\u80de\u7531\u6765\u56e0\u5b50\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066\u3001\u7b2c53\u56de\u6b6f\u79d1\u57fa\u790e\u533b\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30fb\u7dcf\u4f1a\u30012011.10.1\uff08\u5c90\u961c\uff09<\/li>\n
                              16. \u5ddd\u672c\u6cf0\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5c71\u672c\u548c\u5e78\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived microvesicles\u304c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306emotility\u3068Akt\u306e\u6d3b\u6027\u5316\u306b\u5bc4\u4e0e\u3059\u308b\u3001\u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09\u30012011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
                              17. \u5c71\u672c\u548c\u5e78\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5927\u6751\u77b3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u904a\u8d70\u3092\u4fc3\u9032\u3059\u308b\u3001\u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09\u30012011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
                              18. \u5927\u8cc0\u5247\u5b5d\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\u3001\u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09\u30012011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
                              19. \u79cb\u5c71\u5ee3\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u5b9a\u672c\u572d\u5f18\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308bMDR1\u306e\u767a\u73fe\u4ea2\u9032\u3092\u4f34\u3063\u305f\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066\u3001\u7b2c91\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u7dcf\u4f1a\uff08\u7b2c104\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u5206\u79d1\u4f1a\uff09\u30012011.9.17\uff08\u672d\u5e4c\uff09<\/li>\n
                              20. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u95a2\u308f\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027\u3001\u7b2c20\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\u30012011.6.30\uff08\u6d5c\u677e\uff09<\/li>\n
                              21. <\/u>\u5927\u8cc0\u5247\u5b5d\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\u3001\u7b2c20\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\u30012011.6.30\uff08\u6d5c\u677e\uff09<\/li>\n
                              22. \u9593\u77f3\u5948\u6e56\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u5834\u96c4\u4ecb\u3001\u6d5c\u7530\u6df3\u4e00\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u5c71\u672c\u548c\u5e78\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u4e95\u4e0a\u8fb2\u592b\u592b\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u304c\u3093\u8ee2\u79fb\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u7b2c20\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a\u30012011.6.30\uff08\u6d5c\u677e\uff09<\/li>\n
                              23. Akiyama K., Ohga N., Hida Y., Ishikawa S,. Sadamoto Y., Kawamoto T., Kondoh M., Maishi N., Torii C., Kitayama K., Shindoh M.,\u00a0Hida K<\/u>.<\/u>\uff1a<\/strong>Endothelial cells acquire drug resistance by factors from tumor cells. \u7b2c63\u56de\u65e5\u672c\u7d30\u80de\u751f\u7269\u5b66\u4f1a\u5927\u4f1a\u30012011.6.29\uff08\u672d\u5e4c)<\/li>\n<\/ol>\n

                                2010<\/h4>\n
                                  \n
                                1. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5317\u5c71\u548c\u5b50\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5c71\u672c\u548c\u5e78\u3001\u9032\u85e4\u6b63\u4fe1\uff1aTumor induces drug resistance of endothelial cells by nuclear translocation of YB-1 and up-regulation of MDR-1, \u7b2c18\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\uff08\u5927\u962a\uff09<\/li>\n
                                2. \u5927\u8cc0\u5247\u5b5d\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u5317\u5c71\u548c\u5b50\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aComparative characterization of tumor endothelial cells isolated from highly and low metastatic tumors, \u7b2c18\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\uff08\u5927\u962a\uff09<\/li>\n
                                3. \u9593\u77f3\u5948\u6e56\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u5834\u96c4\u4ecb\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u5317\u5c71\u548c\u5b50\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5c71\u672c\u548c\u5e78\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aAnalysis of interaction between tumor endothelial cells and tumor cells, \u7b2c18\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\uff08\u5927\u962a\uff09<\/li>\n
                                4. \u5ddd\u672c\u6cf0\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u5317\u5c71\u548c\u5b50\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5927\u6fa4\u5d07\u5b8f\u3001\u5c71\u672c\u548c\u5e78\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived microvesicles cause gene changes in endothelial cells, \u7b2c18\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\uff08\u5927\u962a\uff09<\/li>\n
                                5. Ohga N, Ishikawa S,. Hida Y., Akiyama K., Kitayama K., KondouM., Maishi N., Kawamoto T., Ohsawa T., Yamamoto K., Shindoh M.and\u00a0Hida K<\/u>*.<\/u>:<\/strong>\u00a0Comparative characterization of tumor endothelial cells isolated from highly and low metastatic tumors, \u7b2c69\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012010.9.22-24\uff08\u5927\u962a\uff09<\/li>\n
                                6. Akiyama K.,Ohga N, Hida Y., Akino T., Kurosu T., Kitayama K.,Ishikawa S., Kondoh M., Maishi N., Kawamoto T., Ohsawa T.,Yamamoto K., Shindoh M.and\u00a0Hida K*.<\/strong><\/u>: Endothelial cells acquire drugresistance by factors from tumor cells, \u7b2c69\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012010.9.22-24\uff08\u5927\u962a\uff09<\/li>\n
                                7. \u9593\u77f3\u5948\u6e56\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u816b\u760d\u7d30\u80de\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u7b2c69\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012010.9.22-24\uff08\u5927\u962a\uff09<\/li>\n
                                8. Kondoh M., Ohga N., Kurosu T., Kitayama K., Akiyama K., MaishiN., Kawamoto T., Ohsawa T., Yamamoto K., Hida Y., Shindoh M. and\u00a0Hida K*.<\/strong><\/u>\u00a0:Gene expression analysis of circulating endothelial cells in cancer patients, \u7b2c69\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012010.9.22-24\uff08\u5927\u962a\uff09<\/li>\n
                                9. Kawamoto T., Ohga N., Kitayama K., Akiyama K., Kondou M., Maishi N., Ohsawa T., Yamamoto K., Hida Y., Shindoh M.and\u00a0Hida K*.<\/u>: Tumor-derived microvesicles cause gene changes in endothelial cells,\u7b2c69\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012010.9.22-24\uff08\u5927\u962a\uff09<\/li>\n
                                10. \u9593\u77f3\u5948\u6e56\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u816b\u760d\u7d30\u80de\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u7b2c64\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\uff08\u672d\u5e4c\uff09\u7b2c64\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012010.6.24-25\uff08\u672d\u5e4c\uff09<\/li>\n
                                11. \u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u4f4e\u9178\u7d20\u74b0\u5883\u306b\u304a\u3051\u308b\u7279\u7570\u6027\u306e\u89e3\u6790\u3001\u7b2c64\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012010.6.24-25\uff08\u672d\u5e4c\uff09\u7b2c64\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012010.6.24-25\uff08\u672d\u5e4c\uff09<\/li>\n
                                12. \u79cb\u5c71\u5ee3\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1aEndothelial cells acquire abnormalities by factors from tumor cells, \u7b2c64\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012010.6.24-25\uff08\u672d\u5e4c\uff09<\/li>\n
                                13. \u9ed2\u9808\u62d3\u90ce\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6771\u91ce\u53f2\u88d5\u3001\u683c\u53e3\u6e09\u3001\u9ed2\u5d8b\u96c4\u5fd7\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bHuR\u3092\u4ecb\u3057\u305fCOX2\u304a\u3088\u3073VEGF-A\u306emRNA\u306e\u767a\u73fe\u4ea2\u9032\u3001\u7b2c64\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012010.6.24-25\uff08\u672d\u5e4c\uff09<\/li>\n
                                14. \u5927\u8cc0\u5247\u5b5d\u3001\u6751\u6728 \u529b\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7dd1\u8336\u30ab\u30c6\u30ad\u30f3EGCG\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u76f4\u63a5\u7684\u306a\u6291\u5236\u52b9\u679c\u3092\u6709\u3059\u308b\u3001\u7b2c64\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30012010.6.24-25\uff08\u672d\u5e4c\uff09<\/li>\n
                                15. \u9593\u77f3\u5948\u6e56\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u79cb\u5c71\u5ee3\u8f14\u3001 \u77f3\u5ddd\u4fee\u5e73\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u5ddd\u672c\u6cf0\u8f14\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u816b\u760d\u7d30\u80de\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u7b2c19\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a2010.6.16-17\uff08\u91d1\u6ca2\uff09<\/li>\n<\/ol>\n

                                  2009<\/h4>\n
                                    \n
                                  1. \u5927\u8cc0\u5247\u5b5d\u3001\u6751\u6728\u529b\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u5bfe\u3059\u308b\u6291\u5236\u6297\u52b9\u679c\u3092\u6709\u3059\u308b\u3001\u7b2c54\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\u30012009.10.9-11\uff08\u672d\u5e4c\uff09<\/li>\n
                                  2. \u9ed2\u9808\u62d3\u90ce\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u683c\u53e3\u6e09\u3001\u9ed2\u5d8b\u96c4\u5fd7\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bHuR\u3092\u4ecb\u3057\u305fCOX2\u304a\u3088\u3073VEGF-A\u306emRNA\u306e\u767a\u73fe\u4ea2\u9032\uff0e\u7b2c54\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\u30012009.10.9-11\uff08\u672d\u5e4c\uff09<\/li>\n
                                  3. \u79cb\u5c71\u5e83\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u201dEndothelial cells acquireabnormalities by factors from tumor cells\u201d\u7b2c17\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u30012009.10.8-9\uff08\u6771\u4eac\uff09<\/li>\n
                                  4. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30ebEGCG\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u5bfe\u3059\u308b\u5236\u5fa1\u52b9\u679c\u3092\u6709\u3059\u308b\u3001\u7b2c17\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u30012009.10.8-9\uff08\u6771\u4eac\uff09<\/li>\n
                                  5. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u3068\u85ac\u5264\u62b5\u6297\u6027\u3001\u7b2c68\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012009.10.1-3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                  6. \u77f3\u5ddd\u4fee\u5e73\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u304b\u3089\u5206\u96e2\u3055\u308c\u305f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790\u3001\u7b2c68\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012009.10.1-3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                  7. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u3000\u529b\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30ebEGCG\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u5bfe\u3059\u308b\u5236\u5fa1\u52b9\u679c\u3092\u6709\u3059\u308b\u3001\u7b2c68\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012009.10.1-3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                  8. \u79cb\u5c71\u5e83\u8f14\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u8fd1\u85e4\u7f8e\u5f25\u5b50\u3001\u9593\u77f3\u5948\u6e56\u3001\u4e95\u4e0a\u8fb2\u592b\u7537\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u764c\u7d30\u80de\u57f9\u990a\u4e0a\u6e05\u306b\u3088\u308b\u6b63\u5e38\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027\u7372\u5f97\u3001\u7b2c68\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012009.10.1-3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                  9. \u9ed2\u9808\u62d3\u90ce\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u683c\u53e3\u6e09\u3001\u9ed2\u5d8b\u96c4\u5fd7\u3001\u79cb\u91ce\u6587\u81e3\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bHur\u3092\u4ecb\u3057\u305fCOX-2\u304a\u3088\u3073VEGFA\u3000mRNA\u306e\u767a\u73fe\u4ea2\u9032\u3001\u7b2c68\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012009.10.1-3\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                  10. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u304b\u3089\u5206\u96e2\u3055\u308c\u305f\uff12\u3064\u306e\u816b\u760d\u8840 \u7ba1\u5185\u76ae\u7d30\u80de\u306e\u6bd4\u8f03\u691c\u8a0e\uff0c\u7b2c18\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a \uff0c2009.7.23-24\uff08\u65ed\u5ddd\uff09<\/li>\n
                                  11. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u8ee2\u79fb\u306b\u304a\u3051\u308b\u304c\u3093\u7d30\u80de\u30fb\u9593\u8cea\u76f8\u4e92\u4f5c\u7528\uff1bThe Role of Cancer-Host Interaction during Metastasis \u201dTumor endothelial cell abnormality\u201d , \u7b2c18\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u30e2\u30fc\u30cb\u30f3\u30b0\u30bb\u30c3\u30b7\u30e7\u30f3, 2009.7.23-24\uff08\u65ed\u5ddd\uff09<\/li>\n
                                  12. \u5317\u6751\u54f2\u4e5f\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u9032\u85e4\u6b63\u4fe1\uff1aDaxx\u306fTNF-a<\/span>\u306b\u3088\u308bJNK\u6d3b\u6027\u5316\u7d4c\u8def\u306b\u91cd\u8981\u306a\u5f79\u5272\u3092\u679c\u305f\u3059\u3001\u7b2c98\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012009.5.1-3\uff08\u4eac\u90fd\uff09<\/li>\n
                                  13. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30ab\u30c6\u30ad\u30f3\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u76f4\u63a5\u7684\u306a\u6291\u5236\u52b9\u679c\u3092\u6709\u3059\u308b. \u7b2c98\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012009.5.1-3\uff08\u4eac\u90fd\uff09<\/li>\n<\/ol>\n

                                    2008\u5e74\u4ee5\u524d<\/h4>\n
                                      \n
                                    1. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u677e\u7530\u5149\u5e73\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3068\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u3078\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c31\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a\u3001\u7b2c81\u56de\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5927\u4f1a\u5408\u540c\u5927\u4f1a\u30012008.12.9-12\uff08\u795e\u6238\uff09<\/li>\n
                                    2. \u5317\u6751\u54f2\u4e5f\u3001\u7530\u4e2d\u5b97\u4e00\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u5800\u8d8a\u4fe1\u592b\u3001\u9032\u85e4\u6b63\u4fe1\uff1aDaxx\u306b\u3088\u308bMAP\u30ad\u30ca\u30fc\u30bc\u6d3b\u6027\u5316\u6a5f\u69cb\u3001\u7b2c31\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a\u3001\u7b2c81\u56de\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5927\u4f1a\u5408\u540c\u5927\u4f1a\u30012008.12.9-12\uff08\u795e\u6238\uff09<\/li>\n
                                    3. \u7530\u4e2d\u5b97\u4e00\u3001\u5317\u6751\u54f2\u4e5f\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aPim-1\u306fTRAF2, ASK-1\u3068\u76f8\u4e92\u4f5c\u7528\u3057JNK\u3092\u4e00\u904e\u6027\u306b\u6d3b\u6027\u5316\u3059\u308b\u3001\u7b2c31\u56de\u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u5e74\u4f1a\u3001\u7b2c81\u56de\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5927\u4f1a\u5408\u540c\u5927\u4f1a\u30012008.12.9-12\uff08\u795e\u6238\uff09<\/li>\n
                                    4. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u5317\u6d77\u9053\u652f\u90e8\u30fb\u65e5\u672c\u751f\u7269\u7269\u7406\u5b66\u4f1a\u5317\u6d77\u9053\u652f\u90e8\u30fb\u5317\u6d77\u9053\u5206\u5b50\u751f\u7269\u7814\u7a76\u4f1a\uff12\uff10\uff10\uff18\u5e74\u5ea6\u5408\u540c\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u751f\u547d\u73fe\u8c61\u306e\u5206\u5b50\u30ec\u30d9\u30eb\u3067\u306e\u89e3\u660e\u300d\u300c\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u300d2008.11.21\u3001\u5317\u6d77\u9053\u5927\u5b66\u5927\u5b66\u9662\u7406\u5b66\u7814\u7a76\u9662\u5927\u8b1b\u7fa9\u5ba4\uff08\u672d\u5e4c\uff09\uff08\u62db\u5f85\u8b1b\u6f14\uff09<\/li>\n
                                    5. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u3078\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c67\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012008.10.28-30\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                                    6. \u677e\u7530\u5149\u5e73\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u9577\u671f\u57f9\u990a\u4e0b\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\u3001\u7b2c88\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u75c5\u7406\u5206\u79d1\u4f1a\uff08\u7b2c41\u56de\u5317\u6d77\u9053\u75c5\u7406\u8ac7\u8a71\u4f1a\uff09\u30012008.9.20\u3001\u672d\u5e4c\uff08\u5317\u6d77\u9053\u5927\u5b66\u533b\u5b66\u90e8\u81e8\u5e8a\u5927\u8b1b\u5802\uff09<\/li>\n
                                    7. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u76f4\u63a5\u7684\u306a\u6291\u5236\u52b9\u679c\u3092\u6709\u3059\u308b. \u7b2c88\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff08\u7b2c95\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff09\u30012008.9.6\u3001\u65ed\u5ddd\uff08\u65ed\u5ddd\u533b\u79d1\u5927\u5b66\uff09<\/li>\n
                                    8. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u77f3\u5ddd\u4fee\u5e73\u3001\u79cb\u5c71\u5e83\u8f14\u3001\u4f50\u6fa4\u967d\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u814e\u764c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7b2c88\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff08\u7b2c95\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\uff09\u30012008.9.6\u3001\u65ed\u5ddd\uff08\u65ed\u5ddd\u533b\u79d1\u5927\u5b66\uff09<\/li>\n
                                    9. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u91ce\u6587\u81e3\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027.\u7b2c73\u56de\u65e5\u672c\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u30fb\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\u7b2c19\u56de\u65e5\u672c\u751f\u4f53\u9632\u5fa1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\u7b2c45\u56de\u88dc\u4f53\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u5408\u540c\u5927\u4f1a\u30012008.7.10-12\uff08\u672d\u5e4c\uff09<\/li>\n
                                    10. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u79cb\u91ce\u6587\u81e3\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027. \u65e5\u672c\u5206\u5b50\u751f\u7269\u5b66\u4f1a\u7b2c\uff18\u56de\u6625\u671f\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u30012008.5.25-27\u3001\u672d\u5e4c\uff08\u4eac\u738b\u30d7\u30e9\u30b6\u30db\u30c6\u30eb\u672d\u5e4c\uff09<\/li>\n
                                    11. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u300c\u816b\u760d\u8840\u7ba1\u306e\u591a\u69d8\u6027\uff0d\u7279\u7570\u7684\u306a\u907a\u4f1d\u5b50\u767a\u73fe\u304b\u3089\u67d3\u8272\u4f53\u7570\u5e38\u307e\u3067\uff0d\u300d\u91d1\u6ca2\u5927\u5b66\u304c\u3093\u7814\u7a76\u6240\u30bb\u30df\u30ca\u30fc\u30012008\u30012008.5.16\u3001\u91d1\u6ca2\uff08\u62db\u5f85\u8b1b\u6f14\uff09<\/li>\n
                                    12. El-Beialy W., Kitamura T.,\u00a0Hida K<\/u>.<\/u><\/strong>, Higashino F., Totsuka Y., Shindoh M.: Enhancing Chemosensitivity of Oral Squamous Carcinomas by Inorganic Poly-Phosphate, \u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
                                    13. \u67f3\u5ddd\u5f69\u3001\u5c71\u91ce\u8302\u3001\u6e0b\u8c37\u667a\u548c\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6a2a\u5c71\u6566\u90ce\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30a2\u30c7\u30ce\u30a6\u30a4\u30eb\u30b9\u30b2\u30ce\u30e0\u306b\u304a\u3051\u308b\u30d2\u30b9\u30c8\u30f3\u30bf\u30f3\u30d1\u30af\u306e\u5f79\u5272\u3001\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
                                    14. \u7530\u4e2d\u5b97\u4e00\u3001\u5317\u6751\u54f2\u4e5f\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u53e3\u8154\u6241\u5e73\u4e0a\u76ae\u304c\u3093\u306b\u304a\u3051\u308bPim-1\u306e\u767a\u73fe\u306f\u7d30\u80de\u904b\u52d5\u80fd\u3092\u4ea2\u9032\u3057\u8ee2\u79fb\u6d3b\u6027\u306b\u95a2\u4e0e\u3059\u308b\u3001\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
                                    15. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u539f\u6797\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u814e\u764c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306eaneuploidy\u3001\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
                                    16. \u9ed2\u9808\u62d3\u90ce\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u79cb\u91ce\u6587\u81e3\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308b\u7279\u7570\u30de\u30fc\u30ab\u30fc\u306e\u89e3\u6790\u3000\u7b2c97\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012008.5.15-17\uff08\u91d1\u6ca2\uff09<\/li>\n
                                    17. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u65b0\u751f\u306e\u30c0\u30a4\u30ca\u30df\u30af\u30b9\uff0d\u591a\u69d8\u306a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\uff0d\u7b2c\uff11\u56de\u6d88\u5316\u5668\u30ea\u30b5\u30fc\u30c1\u30bb\u30df\u30ca\u30fc\u30012008.4.25\u3001\u5e83\u5cf6\u5927\u5b66\uff08\u7279\u5225\u8b1b\u6f14\uff09<\/li>\n
                                    18. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u539f\u6797\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u91ce\u3005\u6751\u514b\u4e5f\uff1a\u814e\u304c\u3093\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7b2c96\u56de\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012008.4.25-27\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    19. \u5927\u8cc0\u5247\u5b5d\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306f\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u76f4\u63a5\u7684\u306a\u5236\u5fa1\u52b9\u679c\u3092\u6709\u3059\u308b\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
                                    20. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aCyclooxygenase-2\u3000inhibitor\u306e\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306a\u3089\u3073\u306b\u8840\u7ba1\u5185\u76ae\u524d\u99c6\u7d30\u80de\u306b\u5bfe\u3059\u308b\u76f4\u63a5\u7684\u5236\u5fa1\u52b9\u679c\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
                                    21. \u677e\u7530\u5149\u5e73\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5206\u96e2\u57f9\u990a\u3068\u305d\u306e\u7279\u7570\u6027\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
                                    22. \u79cb\u91ce\u6587\u81e3\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u6751\u6728\u529b\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u677e\u7530\u5149\u5e73\u3001\u9ed2\u9808\u62d3\u90ce\u3001\u539f\u6797\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u814e\u764c\u306b\u304a\u3051\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u67d3\u8272\u4f53\u7570\u5e38\u3001\u7b2c15\u56de\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012007.11.29-30\uff08\u798f\u5ca1\uff09<\/li>\n
                                    23. Akino T.,\u00a0Hida K*.<\/strong><\/u>, Tsuchiya K., Hida Y., Klagsbrun M., Muraki C., Ohga N., Matsuda K., Harabayashi T., Shinohara N., Nonomura K. and Shindoh M.: Chromosoma abnormalities of tumor endothelial cells in human renal cell carcinoma. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    24. Matsuda K.,\u00a0Hida K*.<\/strong><\/u>, Tsuchiya K., Muraki C., Hida Y., Ohga N., Akino T., Totsuka Y., Klagsbrun M. and Shindoh M.: Isolation and characterization of tumor endothelial cells. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    25. Muraki C.,\u00a0Hida K*.<\/strong><\/u>, Hida Y., Tsuchiya K., Totsuka Y., Klagsbrun M. and Shindoh M.: Anti-angiobenic effects of cyclooxygenase-2 inhibitor on tumor-associated endothelial cells.\u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    26. Kitamura T.,\u00a0Hida K*.<\/strong><\/u>, Higashino F. and Shindoh M.: Phosphorylation of ASK1 stabilizes Daxx and inhibits ist proteasome-dependent degradation.\u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    27. Yanagawa A., Yamano S., Shibuya T., Kitamura T.,\u00a0Hida K*.<\/u>, Higashino F, Yokoyama A and Shindoh M.: MicroRNAs can regulate adenovirus gene expression. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    28. Ohga N.,\u00a0Hida K*.<\/strong><\/u>, Muraki C., Hida Y., Tsuchiya K., Totsuka Y. and Shindoh M.: A green tea plyphenol, EGCG has inhibitory effects on tumor endothelial cells and endothelial progenitor cells. \u7b2c66\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012007.10.3-5\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    29. \u6a0b\u7530\u4eac\u5b50<\/u>:\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u6625\u671f\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u95a2\u3059\u308b\u65b0\u3057\u3044\u6d1e\u5bdf\u30fc\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308b\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u6027\u30012007.10.3-5. 2007\uff08\u6a2a\u6d5c\uff09(\u30b7\u30f3\u30dd\u30b8\u30b9\u30c8)<\/li>\n
                                    30. \u677e\u7530\u5149\u5e73\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u91ce\u6587\u81e3\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u5206\u96e2\u306a\u3089\u3073\u306b\u7279\u7570\u6027\u306e\u89e3\u6790\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
                                    31. \u5c71\u7530\u73e0\u5e0c\u3001\u6d25\u7530\u771f\u5bff\u7f8e\u3001\u5927\u5834\u96c4\u4ecb\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u4e0a\u76ae\u7d30\u80de\u5897\u6b96\u56e0\u5b50\u53d7\u5bb9\u4f53\u963b\u5bb3\u85ac\uff08EGFR-TKI\uff09\u306b\u3088\u308b\u53e3\u8154\u764c\u7d30\u80de\u306e\u984e\u9aa8\u6d78\u6f64\u6291\u5236\u6a5f\u69cb\u306e\u691c\u8a0e\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
                                    32. \u5c71\u672c\u6804\u6cbb\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30dd\u30ea\u30ea\u30f3\u9178\u306e\u7d30\u80de\u5897\u6b96\u306b\u53ca\u307c\u3059\u5f79\u5272\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
                                    33. \u5317\u6751\u54f2\u4e5f\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u9032\u85e4\u6b63\u4fe1\uff1aaxx\u306b\u3088\u308bMAP\u30ad\u30ca\u30fc\u30bc\u30ab\u30b9\u30b1\u30fc\u30c9\u306e\u6d3b\u6027\u5316\u6a5f\u69cb\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
                                    34. \u67f3\u5ddd\u3000\u5f69\u3001\u5c71\u91ce\u3000\u8302\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30a2\u30c7\u30ce\u30a6\u30a4\u30eb\u30b9\u521d\u671f\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u3092\u6291\u5236\u3059\u308bmiRNA\u3001\u7b2c96\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012007.4.19-20\uff08\u5927\u962a\uff09<\/li>\n
                                    35. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u3000\u529b\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u677e\u7530\u5149\u5e73\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u7dd1\u8336\u30dd\u30ea\u30d5\u30a7\u30ce\u30fc\u30eb\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u3078\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c65\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012006.9.28-30\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    36. \u6751\u6728\u3000\u529b\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aCyclooxygenase-2 inhibitor\u306f\u816b\u760d\u8840\u7ba1\u65b0\u751f\u3092\u6291\u5236\u3059\u308b\u3001\u7b2c65\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012006.9.28-30\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    37. \u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u3000\u529b\u3001\u8fd1\u85e4\u3000\u5065\u3001\u4e09\u95a2\u96c5\u7ae0\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u539f\u6797\u3000\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u5c0f\u6797\u6b63\u4f38\uff1aAdrenomecullin antagonist\u767a\u73fe\u30d9\u30af\u30e9\u30fc\u3092\u7528\u3044\u5c45\u305f\u30d2\u30c8\u814e\u764c\u79fb\u690d\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\u306b\u5bfe\u3059\u308b\u907a\u4f1d\u5b50\u6cbb\u7642\u3001\u7b2c65\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u30012006.9.28-30\uff08\u6a2a\u6d5c\uff09<\/li>\n
                                    38. \u6751\u6728\u3000\u529b\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1aCox-2\u963b\u5bb3\u5264\u306b\u3088\u308b\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u6291\u5236\u52b9\u679c\u3001\u7b2c60\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012006.5.11-12\uff08\u540d\u53e4\u5c4b\uff09<\/li>\n
                                    39. \u571f\u5c4b\u90a6\u5f66\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6751\u6728\u3000\u529b\u3001\u8fd1\u85e4\u3000\u5065\u3001\u4e09\u95a2\u54f2\u77e2\u3001\u9032\u85e4\u6b63\u4fe1\u3001\u539f\u6797\u3000\u900f\u3001\u7be0\u539f\u4fe1\u96c4\u3001\u91ce\u3005\u6751\u514b\u4e5f\u3001\u5c0f\u6797\u6b63\u4f38\uff1aAdrenomedullin antagonist\u907a\u4f1d\u5b50\u3092\u7528\u3044\u305f\u30de\u30a6\u30b9\u814e\u764c\u30e2\u30c7\u30eb\u306b\u304a\u3051\u308b\u6297\u816b\u760d\u52b9\u679c. \u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
                                    40. \u5c0f\u91ce\u5bfa\u96c4\u4e00\u90ce\u3001\u5ddd\u6dfb\u7950\u7f8e\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6771\u91ce\u53f2\u88d5\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u30dd\u30ea\u30ea\u30f3\u9178\u306fRac1\u3092\u4ecb\u3057\u3066\u7d30\u80de\u904b\u52d5\u80fd\u306e\u4ea2\u9032\u3092\u3046\u306a\u304c\u3059\u3001\u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
                                    41. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6751\u6728\u3000\u529b\u3001\u5c0f\u6797\u6b63\u4f38\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u7684\u6027\u8cea \u67d3\u8272\u4f53\u907a\u4f1d\u5b50\u5b66\u7684\u7570\u5e38\u306b\u3064\u3044\u3066\u3001\u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
                                    42. \u6751\u6728\u529b\u3001\u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u571f\u5c4b\u90a6\u5f66\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306b\u304a\u3051\u308bCycloocygenase-2 inhibitor\u306e\u4f5c\u7528\u52b9\u679c\u3001\u7b2c95\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30012006.4.30-5.2\uff08\u6771\u4eac\uff09<\/li>\n
                                    43. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u5927\u5ee3\u6d0b\u4e00\u3001\u6238\u585a\u9756\u5247\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7279\u7570\u7684\u6027\u8cea \u67d3\u8272\u4f53\u907a\u4f1d\u5b50\u7570\u5e38\u306b\u3064\u3044\u3066\u3001\u7b2c50\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30012005.10.23-25\u3001\u5927\u962a\uff08\u30e1\u30c0\u30eb\u30c6\u30a3\u30b9\u8cde\u53d7\u8cde\uff09<\/li>\n
                                    44. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u6a0b\u7530\u6cf0\u6d69\u3001\u9032\u85e4\u6b63\u4fe1\uff1a\u816b\u760d\u95a2\u9023\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306f\u7d30\u80de\u767a\u751f\u5b66\u7684\u306b\u7570\u5e38\u3092\u4f34\u3063\u3066\u3044\u308b.\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\uff1b\u8840\u7ba1\u65b0\u751f\uff08\uff12\uff09\u3001\u7b2c64\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u7dcf\u4f1a\u30012005.9.14-16\uff08\u672d\u5e4c\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                                      2025 Munekata T, Matsuda A, Maishi N, Miyamoto I, Hida Y, Hida K. Analysis of tumor metastasis suppression mechanism by the effects of beta-blockers on vascular endothelial cells, \u30dd\u30b9\u30bf\u30fc, \u7b2c33\u56de\u65e5\u672c\u8840\u7ba1\u751f\u7269\u533b\u5b66\u4f1a\u5b66…\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":18,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"publications.php","meta":{"footnotes":""},"class_list":["post-143","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/comments?post=143"}],"version-history":[{"count":71,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/143\/revisions"}],"predecessor-version":[{"id":1496,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/143\/revisions\/1496"}],"up":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/18"}],"wp:attachment":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/media?parent=143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}